Method and kit for preparing complementary DNA

The method for preparing cDNA using a template switch oligonucleotide with UMI and predefined nucleotides addresses the limitations of scRNA-seq by enabling both UMI-based counting and full-length transcript coverage, enhancing the sensitivity and flexibility of single-cell transcriptome profiling.

JP7584420B2Active Publication Date: 2024-11-15BIO BLOCKS AVY +2
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2021536408
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-12-28
Filing Date
2019-12-27
Publication Date
2024-11-15
Estimated Expiration
2039-12-27

AI Technical Summary

Technical Problem

Existing single-cell RNA sequencing (scRNA-seq) methods either lack unique molecular identifier (UMI) compatibility, leading to biased amplification and incomplete transcript coverage, or provide sensitive information but cannot count mRNA molecules within a single cell.

Method used

A method and kit for preparing cDNA that involves hybridizing a cDNA synthesis primer to an RNA molecule, performing template switching with a template switch oligonucleotide (TSO) containing an amplification primer site, UMI, and predefined nucleotides to synthesize an elongated cDNA strand, allowing for both UMI-based counting and full-length transcript coverage.

Benefits of technology

This approach enables simultaneous RNA molecule counting and full-length transcript coverage, providing a more sensitive and flexible profiling of single-cell transcriptomes by combining UMI-based counting with paired-end sequencing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007584420000022
    Figure 0007584420000022
  • Figure 0007584420000023
    Figure 0007584420000023
  • Figure 0007584420000024
    Figure 0007584420000024
Patent Text Reader

Abstract

cDNA is prepared by hybridizing a cDNA synthesis primer to an RNA molecule and synthesizing a cDNA strand complementary to at least a portion of the RNA molecule to form an RNA-cDNA intermediate. A template switching reaction is carried out by contacting the RNA-cDNA intermediate with a template switching oligonucleotide (TSO) under conditions suitable for extending the cDNA strand using the TSO as a template, forming an extended cDNA strand complementary to at least a portion of the RNA molecule and the TSO. The TSO contains an amplification primer site, an identifier tag, a UMI, and multiple predefined nucleotides.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates generally to complementary deoxyribonucleic acid (cDNA) synthesis, in particular to methods and kits for preparing cDNA suitable for sequencing. [Background technology]

[0002] Single-cell ribonucleic acid sequencing (scRNA-seq) has dramatically improved the ability to molecularly profile large numbers of cells, for example to identify and enumerate cell types, subtypes, cell states, and heterogeneous responses to various signals. Essentially all scRNA-seq methods profile RNA molecules that contain polyA tails, e.g., messenger RNA (mRNA) molecules, and can be broadly divided into two main methods.

[0003] The first major method profiles small stretches of bases at either the 5' or 3' end of mRNA molecules with high cellular throughput. These methods include single-cell tagged reverse transcription sequencing (STRT-seq) [1], single-cell sequencing (CEL-seq) [2], massively parallel single-cell RNA sequencing (MARS-seq) [3], 10× Genomics single-cell RNA sequencing [4], split-pool ligation-based transcriptome sequencing (SPLiT-seq) [5], and single-cell combinatorial indexing RNA sequencing (sci-RNA-seq) [6]. All of these methods utilize unique molecular identifiers (UMIs) present in oligo-dT primers or template switching oligonucleotides (TSOs). UMIs are used to remove the biased amplification effect of polymerase chain reaction (PCR). These methods thereby allow counting the mRNA molecules present before amplification.

[0004] The second major method fragments cDNA molecules for subsequent capture of cDNA fragments derived from intact mRNA molecules, thus providing full-length transcript coverage. In particular, methods include Smart-seq[7] and Smart-seq2[8, 10, 11], which provide the most sensitive information of single-cell transcriptomes, i.e., they capture the largest fraction of RNA present in a cell. However, these methods are not compatible with UMI and therefore cannot count mRNA molecules in single cells.

[0005] There is still a need for improvement in the field of RNA sequencing, especially scRNA-seq. Summary of the Invention

[0006] The general goal is to prepare cDNA suitable for sequencing.

[0007] This and other objectives are met by the embodiments defined herein.

[0008] The present invention relates to a method and a kit for preparing cDNA as defined in the independent claims. Further embodiments of the invention are defined in the dependent claims.

[0009] The method for preparing cDNA includes hybridizing a cDNA synthesis primer to an RNA molecule and synthesizing a cDNA strand complementary to at least a portion of the RNA molecule to form an RNA-cDNA intermediate. The method also includes performing a template switching reaction by contacting the RNA-cDNA intermediate with a TSO under conditions suitable for extending the cDNA strand using the TSO as a template to form an extended cDNA strand complementary to the RNA molecule and at least a portion of the TSO. According to the present invention, the TSO includes an amplification primer site, an identification tag, a UMI, and a plurality of predefined nucleotides.

[0010] The kit for preparing cDNA includes a cDNA synthesis primer configured to hybridize to an RNA molecule to allow synthesis of a cDNA strand complementary to at least a portion of the RNA molecule to form an RNA-cDNA intermediate. The kit also includes an amplification primer site, an identification tag, a UMI, and a TSO including a plurality of predefined nucleotides. The TSO is configured to function as a template in a template switching reaction including extension of a DNA strand to form an extended cDNA strand complementary to the RNA molecule and at least a portion of the TSO.

[0011] The present invention allows for the use of UMIs, thus eliminating amplification bias, while still providing full-length transcript coverage. This is possible through the use of the TSOs of the present invention that introduce UMIs into the extended cDNA strand.

[0012] The embodiments, together with further objects and advantages thereof, may best be understood by reference to the following description taken in conjunction with the accompanying drawings, in which: [Brief description of the drawings]

[0013] [Figure 1A] We show the construction of single-cell RNA sequencing libraries for combined full-length transcript coverage and UMI. Individual cells were lysed in individual reaction vessels (e.g., individual tubes, wells of multiwell plates, nanowells or microwells, or chambers of microfluidic devices or droplets) and subjected to reverse transcription and template switching. The resulting first-strand cDNA was pre-amplified, during which a complete Nextera P5 adapter sequence was inserted at the 5' end. The double-stranded cDNA was subjected to tagging, PCR-mediated indexing, and ILLUMINA® sequencing. [Figure 1B]We show the construction of single-cell RNA sequencing libraries for combined full-length transcript coverage and UMI. Individual cells were lysed in individual reaction vessels (e.g., individual tubes, wells of multiwell plates, nanowells or microwells, or chambers of microfluidic devices or droplets) and subjected to reverse transcription and template switching. The resulting first-strand cDNA was pre-amplified, during which a complete Nextera P5 adapter sequence was inserted at the 5' end. The double-stranded cDNA was subjected to tagging, PCR-mediated indexing, and ILLUMINA® sequencing. [Diagram 2] 1 shows box plots illustrating improved gene detection according to the present invention. [Diagram 3] Panels A and B show detailed RNA biotype detection using Smart-seq2 of the present invention and the prior art. [Figure 4] Controls for the levels of 5' end reads and internal reads are shown. [Diagram 5] Panels A to C show the cDNA length distribution of the different tagged cDNAs. [Figure 6] Panels A through C show increased gene detection by altering reaction conditions and experimental additives. [Figure 7] Panels A and B show the read coverage across an RNA molecule for internal reads and UMI-containing 5'-end reads, respectively. [Figure 8] 1 is a flow chart showing a method for preparing cDNA according to an embodiment. [Figure 9a] We present the library strategy for an embodiment of the invention called Smart-seq3. PolyA+ RNA molecules are reverse transcribed and template switching is performed at the 5' end. After PCR pre-amplification, Tn5-mediated tagging introduces near-random cuts into the cDNA, generating 5'UMI-tagged fragments and internal fragments spanning the entire gene body. [Figure 9b]Gene body coverage averaged across HEK293FT (n=96) cells sequenced with the Smart-seq3 protocol. Shown is the average coverage of UMI reads (green) and internal reads (blue) shaded with standard deviation. [Figure 9c] Effect of tagmentation conditions on the fraction of UMI-containing reads (16 HEK293FT cells per condition). Left panel: Varying Tn5 with a constant cDNA input of 200pg. Right panel: Varying cDNA input with a constant Tn5 of 0.5ul. [Figure 9d] Gene detection sensitivity of Smart-seq2 (44 cells) and Smart-seq3 (88 cells), downsampled to 1 million raw reads per HEK293FT cell. Shown is the number of genes detected with an RPKM of 0 or 1. P values ​​were calculated as two-tailed t-tests. [Figure 9e] Reproducibility in gene expression quantification across HEKF293FT cells for Smart-seq2 (44 cells) and Smart-seq3 (88 cells) at the RPKM and UMI levels. Shown is adjusted r2 for all pairwise cell-to-cell linear model fits in libraries downsampled to 1 million reads per cell. [Figure 9f] Figure 1 shows the sensitivity of Smart-seq3 to detect RNA molecules as shown by summarizing the number of unique error-corrected UMI sequences and genes detected per HEK293FT cell. Colors indicate downsampling depth per cell ranging from 10,000 (n = 24 cells) to 750,000 (n = 16 cells) UMI-containing sequencing reads. [Figure 9g] Violin diagram summarizing the number of molecules detected per cell using Smart-seq2-UMI, Smart-seq3, and using smRNA-FISH for four X-chromosome genes (Hdac6, Igbp1, Mpp1, and Msl3). [Figure 9h]The percentage of smRNA-FISH molecules detected in cells is estimated using Smart-seq2-UMI and Smart-seq3. Shown are the means and 95% confidence intervals. [Figure 10] An overview of Smart-seq3 sequencing conditions and replicates is shown. Each row shows the reaction condition tested and the number of genes detected in individual HEK293FT cells with 1M raw fastq reads. The number of individual cells with at least 1 million sequenced reads per condition is listed on the right. Several earlier versions of Smart-seq2 with elements of Smart-seq3 chemistry are included in this figure as "Smart-seq2.5". The exact reaction conditions per row are listed in Table 4. [Figure 11] The effect of salt, PEG and additives on Smart-seq3 reverse transcription is shown. A shows a test of the performance of Maxima H Minus reverse transcription reactions in various reaction conditions. For each condition, box plots are summarized with the number of unique UMIs detected in individual HEK293FT cells at 1M raw fastq reads. Reverse transcription was tested in the context of using NaCl, CsCl or a standard KCl-based buffer. In addition, the effect of adding 5% PEG or 1 mM dCTP (16 cells per condition) was evaluated. B shows reaction conditions as in A (16 cells per condition) summarized against the number of genes identified from 1 million raw UMI reads per cell. C shows reaction conditions as in A (16 cells per condition) summarized against the number of genes identified from 1 million raw reads per cell (subsampling from both 5'UMI reads and internal reads). [Figure 12]We show improved detection of protein-coding and non-coding RNAs by Smart-seq3. In A, a variant of the Smart-seq3 reaction shows improved detection of protein-coding genes and also genes of different biotypes such as poly-A+ lincRNA, antisense RNA, processed pseudogenes, processed transcripts, and snoRNAs compared to previous experiments of Smart-seq2 and Smart-seq2 using UMIs (here called "intermediate"). B shows genes with similar RNA biotypes detected by UMIs including reads of Smart-seq2 and Smart-seq3 variants using UMIs (here called "intermediate"). [Figure 13a] Single-cell RNA counting at allele and isoform resolution is shown, along with a strategy to obtain allele and isoform resolved information using Smart-seq3. Red crosses indicate transcription positions with inter-allele genetic variation. After tagging, UMI fragments are subjected to paired-end sequencing (shown in green) to link molecular counting 5' ends with different gene body fragments that can cover allele-informative variant positions and span isoform-informative splice junctions, thus allowing in silico reconstruction of isoforms with their allele of origin. [Figure 13b] The average percentage of molecules that could be assigned to an allelic origin based on the SNPs covered from 369 individual CAST / EiJ × C57 / Bl6J hybrid mouse fibroblasts is shown. Only genes detected in >5% of cells were considered (n = 15,158 genes). [Figure 13c] (c) Effect of transcript length and number of exonic SNPs on allele assignment of RNA molecules. Shown are genes (n=15,158) grouped into 50 2D bins colored by the average per-gene percentage of molecules assigned to the allele of origin. The inset shows the number of genes per visualized bin. [Figure 13d]Figure 1 shows the agreement between allelic expression from RNA counts and conventional estimates based on separated expression and allelic fractions from internal reads. Shown is the average CAST allelic fraction for 15,158 genes in 369 mouse fibroblasts. Dots are colored by the local density of the data point. [Figure 13e] Shown are results from linear models comparing direct allele RNA counts to previous read-based estimates of allele expression in each of 369 individual fibroblasts. For each cell (n=369), a linear model fit of the CAST allele fraction between the direct reconstructed molecular assignments and the previous read-based estimates was calculated. Shown are boxplots of the intercept, slope, and r^2 values ​​obtained from each linear model per cell. [Figure 13f] We demonstrate the improved ability of Smart-seq3 to infer transcriptional burst kinetics compared to Smart-seq2-UMI (Smart-seq2 chemistry combined with UMI in TSO). Inference was performed in F1 CAST / EiJ × C57 / Bl6J mouse fibroblasts, and Spearman correlations between CAST and C57 kinetics across genes for burst size and frequency are shown. Additionally, the x-axis indicates the number of genes for which burst kinetics can be reliably inferred. [Figure 13g] The number of RNA molecules (x-axis, log10) reconstituted to different lengths (in base pairs, y-axis) is summarized, showing only molecules that were additionally assigned to unique transcript isoforms. In total, 1 million of the longest reconstituted RNA molecules are shown from one experiment with 369 mouse fibroblasts, with the molecules shown in descending order. [Figure 13h] Sashimi plots are shown visualizing two reconstructed RNA transcripts supporting two distinct transcript isoforms of Cox7a2l (ENSMUST00000167741 in orange, and ENSMUST00000025095 in light blue) observed in mouse fibroblasts (cell barcode: TTCCGTTCGCGACTAA). [Figure 13i]Violin diagram showing the percentage of detected molecules that could be assigned to a specific Ensembl transcript isoform per F1 CAST / EiJ × C57 / Bl6J mouse fibroblast. Shown are results for all Ensembl genes or the subset with two or more annotated isoforms ("multiisoform genes"). The median percentage of assigned molecules per cell was 52.37% and 41.04% for all genes and multiisoform genes, respectively. [Figure 13j] Figure 1 shows visualization of significant lineage-specific isoform expression in mouse fibroblasts colored by chromosome. The Y-axis shows Benjamini-Hochberg corrected p-values ​​(-log10) from individual chi-square tests performed for each gene assessing the association between allelic origin and isoform. [Figure 13k] Visualization of significant lineage-specific isoform expression of Hcfc1r1 in CAST / EiJ and C57 / Bl6J mouse strains. Violin diagram shows isoform expression in mouse fibroblasts, separated by lineage and isoform. Top shows isoform structure of the transcript. [Figure 14] Visualization of read pairs from a single transcript molecule from the Cox7a2 locus in primary fibroblasts. Visualization of read pairs sequenced from one molecule from the Cox7a2l locus. Top: Exons and introns of the Cox7a2l locus shown in genomic coordinates (mm10). Each row represents a unique read pair, orange boxes indicate mapping of sequences to genomic loci, dotted lines indicate sequences are connected by read pairs, and solid lines indicate exon-intron junctions were captured in the sequenced reads. Note that all combined read pairs span essentially the complete transcript, i.e., for this molecule, the complete transcript could be reconstructed. [Figure 15]Detailed comparison of burst kinetics inference based on Smart-seq2-UMI and Smart-seq3 data is shown. a, Scatter plot showing estimated burst frequency for C57 (x-axis) and CAST (y-axis) alleles for genes in mouse fibroblasts. The plot on the left shows the results based on Smart-seq3 data, and the panel on the right shows the results using Smart-seq2-UMI data. b, Scatter plot showing estimated burst size for C57 (x-axis) and CAST (y-axis) alleles for genes in mouse fibroblasts. The plot on the left shows the results based on Smart-seq3 data, and the panel on the right shows the results using Smart-seq2-UMI data. [Figure 16] Species mixing and doublets in Smart-seq3. a, Scatter plot showing the number of reads aligned to human (x-axis) and mouse (y-axis) for a complex HCA sample containing both human, mouse, and dog cells. b, Scatter plot showing the number of reads aligned to human (x-axis) and dog (y-axis) for a complex HCA sample containing both human, mouse, and dog cells. Very few cells are shown to show any signal towards more than one genome, indicating a very low doublet rate. [Figure 17a] We show a Smart-seq3 analysis of a complex human sample, showing the dimensionality reduction (UMAP) of 3,890 human cells sequenced with the Smart-seq3 protocol and color-coded by annotated cell type. [Figure 17b] Comparison of gene detection sensitivity between Smart-seq2 and Smart-seq3 in various cell types. Cells are downsampled to 100k raw reads per cell and t-test p-values ​​are annotated for each pairwise comparison. [Figure 17c] 1 shows a heatmap depicting gene expression of select marker genes that were expressed at statistically significantly different levels in naive and memory B cells. The color scale represents normalized and scaled expression values. [Figure 17d]The percentage of reconstituted RNA molecules that could be assigned to a single Ensembl isoform, separated by cell type, is shown. [Figure 17e] Matrix showing the fraction of reconstituted molecules that could be assigned to either one or N isoforms, molecules were first grouped by the number of annotated isoforms available for that gene. [Fig. 17f] Matrix showing the fraction of reconstituted molecules that could be assigned to either one or N isoforms (as in e) after filtering for assignment to only those isoforms with detectable expression (TPM>0) in Salmon (including internal reads without linked UMIs). [Figure 17g] 1 is a bar plot showing the fraction of molecules that are assigned to different PTPRC isoforms, separated by cell type, and aggregated across all cells in a cell type. [Figure 17h] Shown is a sashimi plot of remodeling molecules assigned to either the R0 or RABC isoforms of the PTPRC in gamma delta T cells. [Figure 17i] A bar plot showing the fraction of molecules that can be assigned to different TIMP1 isoforms, separate by cell type, and aggregate across cells within a cell type is shown. [Figure 17j] Sashimi plot of remodeling molecules assigned to two TIMP1 isoforms in FCGR3A+ monocytes is shown. [Figure 18a] Figure 1 represents mapping statistics for the Smart-seq2 and Smart-seq3 libraries used, showing the percentage of unmapped read pairs, as well as read pairs that aligned to exonic, intronic, and intergenic regions, separated per protocol (Smart-seq2 and Smart-seq3) and experiment (HEK293FT, mouse fibroblasts, HCA cells). [Figure 18b]Mapping statistics for the Smart-seq2 and Smart-seq3 libraries used are presented, showing mapping statistics for 5'UMI-containing read pairs for Smart-seq3. Percentages of unmapped read pairs, as well as read pairs that aligned to exonic, intronic, and intergenic regions, are shown. Separate per experiment (HEK293FT, mouse fibroblasts, HCA cells). [Figure 19] 1 illustrates a method for generating 5'UMI reads and internal reads from which the full-length sequence of an RNA is then constructed, according to an embodiment of the invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] A barcode is a region that functions as an identifier for a nucleic acid. Barcodes can be of various types, examples of which include, for example, cell barcodes, RNA source barcodes such as host barcodes, container barcodes such as plate or well barcodes, in-line barcodes, indexing barcodes, etc.

[0015] Unique molecular identifiers (i.e., UMIs) are randomers of various lengths, e.g., ranging from 6-12 nt in length, that can be used to count individual molecules of a given molecular species. Counting is accomplished by attaching UMIs from a diverse pool of UMIs to individual molecules of a target of interest, such that each individual molecule receives a unique UMI. By counting individual transcript molecules, PCR bias can be reduced during NGS library preparation, and a more quantitative understanding of a sample population can be achieved. See, e.g., U.S. Pat. No. 8,835,358; Fu et al., "Molecular Indexing Enables Quantitative Targeted RNA Sequencing and Reveals Insufficient Efficiency in Standard Library Preparation," PNAS (2014) 5:1891-1896; and Fu et al., "Digital Encoding of Cellular mRNAs Enabling Accurate and Absolute Gene Expression Measurements by Single Molecule Counting," Anal.Chem (2014) 86:2867-2870.

[0016] The term "complementary" as used herein refers to a nucleotide sequence that base pairs by non-covalent binding to all or a region of a target nucleic acid (e.g., a template RNA or other region of a double-stranded product nucleic acid). In standard Watson-Crick base pairing, adenine (A) base pairs with thymine (T), as does guanine (G) with cytosine (C) in DNA. In RNA, thymine is replaced by uracil (U). Thus, A is complementary to T and G is complementary to C. In RNA, A is complementary to U and vice versa. Typically, "complementary" refers to a nucleotide sequence that is at least partially complementary. The term "complementary" may also include a duplex that is fully complementary such that every nucleotide of one strand is complementary to every nucleotide of the other strand at the corresponding position. In certain cases, a nucleotide sequence may be partially complementary to a target, and not every nucleotide is complementary to every nucleotide in the target nucleic acid at every corresponding position. For example, a primer can be perfectly (i.e., 100%) complementary to a target nucleic acid, or the primer and target nucleic acid can share a degree of complementarity that is less than perfect (e.g., 70%, 75%, 85%, 90%, 95%, 99%). The percent identity of two nucleotide sequences can be determined by aligning the sequences for optimal comparison purposes (e.g., gaps can be introduced into the sequence in the first sequence for optimal alignment). Nucleotides at corresponding positions are then compared, and the percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical positions / total number of positions x 100). If a position in one sequence is occupied by the same nucleotide as the corresponding position in the other sequence, the molecules are identical at that position. A non-limiting example of such a mathematical algorithm is described in Karlin et al., Proc. Natl. Acad. Sci. USA 90:5873-5877 (1993).Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0), as described in Altschul et al., Nucleic Acids Res.25:389-3402 (1997).When using BLAST and Gapped BLAST programs, the default parameters of each program (e.g., NBLAST) can be used.In one embodiment, parameters for sequence comparison can be set as score=100, word length=12, or can be changed (e.g., word length=5 or word length=20).

[0017] As used herein, the term "hybridization conditions" refers to conditions under which a primer will specifically hybridize to a region of a target nucleic acid (e.g., a template RNA or other region of a double-stranded product nucleic acid). Whether a primer specifically hybridizes to a target nucleic acid depends on the degree of complementarity between the polymer and the target nucleic acid and the melting temperature (T M The melting temperature is determined by factors such as the temperature at which hybridization occurs, which can be seen by the melting temperature (T) of the duplex. The melting temperature refers to the temperature at which half of the primer-target nucleic acid duplex remains hybridized and half of the duplex dissociates into single strands. m is the following formula T m =81.5+16.6(log10[Na + ])+0.41(fraction G+C)-(60 / N), where N is the chain length, [Na + ] is less than 1M. Sambrook and Russell (2001; Molecular Cloning: A Laboratory Manual, 3 rd ed., Cold Spring Harbor Press, Cold Spring Harbor NY, Ch. 10). Other, more sophisticated models that depend on a variety of parameters also describe the T of the primer / target duplex in response to different hybridization conditions. mApproaches to achieving specific nucleic acid hybridization can be found, for example, in Tijssen, Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes, Part I, Chapter 2, "Overview of Hybridization Principles and Strategies for Nucleic Acid Probe Assays," Elsevier (1993).

[0018] Next generation sequencing (NGS) library is a library whose nucleic acid members contain partial or complete sequencing platform adapter sequences at their ends, which are useful for sequencing using a target sequencing platform. Target sequencing platforms include, but are not limited to, Illumina®'s HiSeq™, MiSeq™ and Genome Analyzer™ sequencing systems, Ion Torrent™'s Ion PGM™ and Ion Proton™ sequencing systems, Pacific Biosciences' PACBIO RS II Sequel system, Life Technologies™'s SOLiD sequencing system, Roche's 454 GS FLX+ and GS Junior sequencing systems, Oxford Nanopore's MinION™ system, or any other target sequencing platform.

[0019] "Under conditions suitable for cDNA extension" refers to reaction conditions that allow for polymerase-mediated extension of the 3' end of the first strand cDNA primer hybridized to the template RNA, template switching of the polymerase to the template switch oligonucleotide (TSO), and continuation of the extension reaction using the template switch oligonucleotide as a template. Achieving suitable reaction conditions may include selecting reaction mixture components, their concentrations, and reaction temperature to create an environment in which the polymerase is active and the associated nucleic acids in the reaction interact (e.g., hybridize) with each other in a desired manner. For example, in addition to the template RNA, polymerase, first strand cDNA primer, template switch oligonucleotide, and dNTPs, the reaction mixture may contain suitable pH, salt concentration (e.g., KCl concentration), metal cofactor concentration (e.g., MgCl concentration), and / or metal cofactor concentration (e.g., MgCl concentration) for the extension reaction and template switching to occur. 2+ or Mn 2+ The reaction mixture may include buffer components that establish the concentration of GC-rich sequences (e.g., RNase inhibitors and / or DNase inhibitors), one or more additives to facilitate amplification / replication of GC-rich sequences (e.g., GC-Melt™ Reagent (Takara Bio USA, Inc. (Mountain View, Calif.)), betaine, DMSO, ethylene glycol, 1,2-propanediol, or combinations thereof), one or more molecular crowding agents (e.g., polyethylene glycol, ficoll, dextran, etc.), one or more enzyme stabilizing components (e.g., DTT, or TCEP, present at a final concentration ranging from 1-10 mM (e.g., 5 mM)), and / or any other reaction mixture components useful for facilitating polymerase-mediated extension reactions and template switching.

[0020] The reaction mixture can have a pH suitable for primer extension reaction and template switching. In certain embodiments, the pH of the reaction mixture is in the range of 5 to 9, such as 7 to 9, including 8 to 9, for example, 8 to 8.5. In some cases, the reaction mixture includes a pH adjuster. pH adjusters of interest include, but are not limited to, sodium hydroxide, hydrochloric acid, phosphate buffer, citrate buffer, and the like. For example, the pH of the reaction mixture can be adjusted to a desired range by adding an appropriate amount of pH adjuster.

[0021] The temperature range suitable for extension of cDNA may vary according to factors such as the particular polymerase employed, the melting temperature of any optional primers employed, etc. According to one embodiment, the reaction mixture conditions include subjecting the reaction mixture to a temperature ranging from 4°C to 72°C, such as 16°C to 70°C, for example, from 37°C to 50°C, such as 40°C to 45°C, including 42°C.

[0022] The template ribonucleic acid (RNA) molecule in an RNA sample can be a polymer of any length composed of ribonucleotides, for example, 10 nt or more, 20 nt or more, 50 nt or more, 100 nt or more, 500 nt or more, 1000 nt or more, 2000 nt or more, 3000 nt or more, 4000 nt or more, 5000 nt or more, or more than nt. In certain embodiments, the template ribonucleic acid (RNA) can be a polymer composed of ribonucleotides, for example, 10 nt or less, 20 nt or less, 50 nt or less, 100 nt or less, 500 nt or less, 1000 nt or less, 2000 nt or less, 3000 nt or less, 4000 nt or less, or 5000 nt or less, 10,000 nt or less, 25,000 nt or less, 50,000 nt or less, 75,000 nt or less, 100,000 nt or less. The template RNA can be any type of RNA (or subtype thereof), including but not limited to messenger RNA (mRNA), microRNA (miRNA), small interfering RNA (siRNA), trans-acting small interfering RNA (ta-siRNA), naturally occurring small interfering RNA (nat-siRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), small nucleolar RNA (snoRNA), small nuclear RNA (snRNA), long non-coding RNA (lncRNA), non-coding RNA (ncRNA), transfer messenger RNA (tmRNA), precursor messenger RNA (pre-mRNA), small Cajal body specific RNA (scaRNA), piwi interacting RNA (piRNA), endoribonuclease-prepared siRNA (esiRNA), small temporal RNA (stRNA), signal recognition RNA, telomeric RNA, ribozyme, viral RNA, or any combination of these RNA types or subtypes thereof.

[0023] The RNA sample comprising template RNA can be combined into a reaction mixture in an amount sufficient to generate product nucleic acid. According to one embodiment, the RNA sample is combined into a reaction mixture such that the final concentration of RNA in the reaction mixture is 1 fg / μL to 10 μg / μL, such as 1 pg / μL to 5 μg / μL, such as 0.001 μg / μL to 2.5 μg / μL, such as 0.005 μg / μL to 1 μg / μL, such as 0.01 μg / μL to 0.5 μg / μL, including 0.1 μg / μL to 0.25 μg / μL. In certain aspects, the RNA sample comprising template RNA is isolated from a single cell. In other aspects, the RNA sample comprising template RNA is isolated from cells comprising 2, 3, 4, 5, 6, 7, 8, 9, 10 or more, 20 or more, 50 or more, 100 or more, or 500 or more cells, 750 or more cells, 1,000 or more cells, 2,000 or more cells, 5,000 or more cells.In some cases, the RNA sample can be prepared from tissue samples.According to certain embodiments, the RNA sample comprising template RNA is isolated from 500 or less, 100 or less, 50 or less, 20 or less, 10 or less, 9, 8, 7, 6, 5, 4, 3 or 2 cells.

[0024] The template RNA may be present in any nucleic acid sample of the subject, including but not limited to nucleic acid samples isolated from a single cell, multiple cells (e.g., cultured cells), tissues, organs, or organisms (e.g., bacteria, yeast, or higher eukaryotes such as plants, mice, or worms). In certain embodiments, the nucleic acid sample is isolated from a cell(s), tissue, organ, and / or the like, including but not limited to embryos, blastocysts, spent medium from embryo culture or other cells, tissues, or organ culture medium. In other embodiments, the sample may be isolated from a body compartment suitable for use in diagnosis, such as blood, urine, saliva, platelets, microvesicles, exosomes, serum, or other bodily fluids. In some embodiments, the initial nucleic acid sample is obtained from a mammal (e.g., a human, a rodent (e.g., a mouse), or any other mammal of interest). In other embodiments, the nucleic acid sample is isolated from a non-mammalian source, such as bacteria, yeast, insects (e.g., Drosophila), amphibians (e.g., frogs (e.g., Xenopus), viruses, plants, or any other non-mammalian nucleic acid sample source. Approaches, reagents, and kits for isolating RNA from such sources are known in the art. Kits for isolating RNA from a source of interest are commercially available, such as, for example, NucleoSpin®, NucleoMag®, and NucleoBond® RNA isolation kits from Clontech Laboratories, Inc. (Mountain View, CA). In certain embodiments, RNA is isolated from fixed biological samples, such as formalin-fixed, paraffin-embedded (FFPE) tissue. RNA from FFPE tissue can be isolated using commercially available kits, such as NucleoSpin® FFPE RNA kits from Clontech Laboratories, Inc. (Mountain View, CA).

[0025] A variety of polymerases may be employed when carrying out the subject method. The polymerase combined in the reaction mixture in a template switching reaction is capable of template switching, in which the polymerase uses a first nucleic acid strand as a template for polymerization and then switches to the 3' end of a second "acceptor" template nucleic acid strand to continue the same polymerization reaction (e.g., template switching). In certain embodiments, the polymerase combined in the reaction mixture is a reverse transcriptase (RT). Reverse transcriptases capable of template switching that find use in practicing the method include, but are not limited to, retroviral reverse transcriptase, retrotransposon reverse transcriptase, retroplasmid reverse transcriptase, retron reverse transcriptase, bacterial reverse transcriptase, group II intron-derived reverse transcriptase, and mutants, variants, derivatives, or functional fragments thereof, such as RNase H Minus or RNase H reductase (e.g., Superscript RT or Maxima H Minus RT (Thermo Fisher)). For example, the reverse transcriptase can be Moloney Murine Leukemia Virus Reverse Transcriptase (MMLVRT) or silkworm reverse transcriptase (e.g., silkworm R2 non-LTR element reverse transcriptase). Template-switching capable polymerases that find use in practicing the subject methods are commercially available, including SMARTScribe™ reverse transcriptase available from Takara Bio USA, Inc. (Mountain View, CA). In certain embodiments, a mix of two or more different polymerases is added to the reaction mixture, for example, for improved processivity, proofreading, and / or the like. In some cases, the polymer is heterologous to the template or its source. The polymerases are combined in the reaction mixture such that the final concentration of the polymerase is sufficient to generate the desired amount of product nucleic acid. In certain embodiments, the polymerase (e.g., a reverse transcriptase such as MMLVRT or silkworm RT) is present in the reaction mixture at a final concentration of 0.1 to 200 units per μL (U / μL), such as 0.5-100 U / μL, such as 1-50 U / μL, such as 5-25 U / μL, including 20 U / μL.

[0026] In addition to template switching capabilities, the polymerase combined in the reaction mixture may contain other useful functions to facilitate the generation of product nucleic acids. For example, the polymerase may have terminal transferase activity, where the polymerase can catalyze the template-independent addition of deoxyribonucleotides to the 3' hydroxyl end of a DNA molecule. In certain embodiments, when the polymerase reaches the 5' end of the template RNA, the polymerase can incorporate one or more additional nucleotides at the 3' end of the nascent strand that are not encoded by the template. For example, when the polymerase has terminal transferase activity, the polymerase may be able to incorporate 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more additional nucleotides at the 3' end of the nascent DNA strand. In certain embodiments, the polymerase with terminal transferase activity incorporates 10 or less additional nucleotides, such as 5 or less (e.g., 3) at the 3' end of the nascent DNA strand. All nucleotides may be the same (e.g., creating a homonucleotide stretch at the 3' end of the nascent strand), or at least one of the nucleotides may be different from the other(s). In certain aspects, the terminal transferase activity of the polymerase results in the addition of a homonucleotide stretch of 2, 3, 4, 5, 6, 7, 8, 9, 10 or more identical nucleotides (e.g., all dCTPs, all dGTPs, all dATPs, or all dTTPs). According to certain embodiments, the terminal transferase activity of the polymerase results in the addition of a homonucleotide stretch of 10 or less, e.g., 9, 8, 7, 6, 5, 4, 3, or 2 (e.g., 3) identical nucleotides. For example, according to one embodiment, the polymerase is MMLV reverse transcriptase (MMLV RT). MMLV RT incorporates additional nucleotides (mainly dCTPs, e.g., 3 dCTPs) at the 3' end of the nascent DNA strand.As described in more detail elsewhere herein, these additional nucleotides can be useful, for example, to allow hybridization between the 3' end of the template switch oligonucleotide and the 3' end of the nascent DNA strand to facilitate template switching by a polymerase from a template RNA to the template switch oligonucleotide. For example, if a homonucleotide stretch is added to the nascent cDNA strand, the template switch oligonucleotide can have a 3' hybridization domain that is complementary to the homonucleotide stretch to allow hybridization between the 3' end of the template switch oligonucleotide and the 3' end of the nascent cDNA strand. Similarly, if a heteronucleotide stretch is added to the nascent cDNA strand, the template switch oligonucleotide can have a 3' hybridization domain that is complementary to the heteronucleotide stretch to allow hybridization between the 3' end of the template switch oligonucleotide and the 3' end of the nascent cDNA strand.

[0027] A cDNA synthesis primer is a primer that initiates synthesis of first strand cDNA using RNA as a template. According to certain embodiments, the cDNA synthesis primer comprises two or more domains. For example, the primer may comprise a first (e.g., 3') domain that hybridizes to the template RNA and a second (e.g., 5') domain that does not hybridize to the template RNA. The sequences of the first and second domains may be independently defined or may be arbitrary. In certain aspects, the first domain has a defined sequence (e.g., an oligo dT sequence or an RNA-specific sequence) or an arbitrary sequence (e.g., a random sequence such as a random hexamer sequence), and the sequence of the second domain is a defined amplification primer site, e.g., a PCR primer site, e.g., a reverse amplification primer site. In embodiments, the amplification primer site may be the same or different from the amplification primer site of the template switch oligonucleotide.

[0028] By "sequencing platform adapter construct" is meant a nucleic acid construct that includes at least a portion of a nucleic acid domain (e.g., a sequencing platform adapter nucleic acid sequence) utilized by a sequencing platform of interest, such as the sequencing platforms provided by: Illumina® (e.g., HiSeq™, MiSeq™, and / or Genome Analyzer™ sequencing systems); Ion Torrent™ (e.g., Ion PGM™ and / or Ion Proton™ sequencing systems); Pacific Biosciences (e.g., PACBIO RS II sequencing system); Life Technologies™ (e.g., SOLiD sequencing system); Roche (e.g., 454GS FLX+ and / or GS Junior sequencing systems); or any other sequencing platform of interest.In certain embodiments, the sequencing platform adapter construct comprises one or more nucleic acid domains selected from the following: a domain (e.g., a "capture site" or "capture sequence") that specifically binds to a sequencing platform oligonucleotide attached to a surface (e.g., a P5 or P7 oligonucleotide attached to the surface of a flow cell of an Illumina® sequencing system); a sequencing primer binding domain (e.g., a domain to which the Read 1 or Read 2 primer of the Illumina® platform may bind); a barcode domain (e.g., a domain that uniquely identifies the sample source of the nucleic acid to be sequenced to enable sample multiplexing by marking every molecule from a given sample with a specific barcode or "tag"); a barcode sequencing primer binding domain (a domain to which the primer used to sequence the barcode binds); a molecular identification domain (e.g., a molecular index tag such as a randomized tag of 4, 6, or other number of nucleotides) to uniquely mark a molecule of interest to determine expression levels based on the number of instances in which a unique tag is sequenced); or any combination of such domains. In certain aspects, the barcode domain (e.g., sample index tag) and the molecular identification domain (e.g., molecular index tag) can be included in the same nucleic acid. The sequencing platform adaptor domain, when present, can include one or more nucleic acid domains of any length and sequence suitable for the sequencing platform of interest. In certain aspects, the nucleic acid domain is 4 to 200 nt in length. For example, the nucleic acid domain can be 4 to 100 nt in length, e.g., 6 to 75, 8 to 50, or 10 to 40 nt in length. According to certain embodiments, the sequencing platform adaptor construct includes a nucleic acid domain that is 2 to 8 nucleotides in length, e.g., 9 to 15, 16 to 22, 23 to 29, or 30 to 36 nt in length.

[0029] The nucleic acid domain may have a length and sequence that allows a polynucleotide (e.g., an oligonucleotide) employed by the subject sequencing platform to specifically bind to the nucleic acid domain, for example, for solid-phase amplification and / or sequencing by synthesis of cDNA inserts adjacent to the nucleic acid domain. Examples of nucleic acid domains include the P5 (5'-AATGATACGGCGACCACCGA-3') (SEQ ID NO:01), P7 (5'-CAAGCAGAAGACGGCATACGAGAT-3') (SEQ ID NO:02), lead 1 primer (5'-ACACTCTTTCCCTACACGACGCTCTTCCGATCT-3') (SEQ ID NO:03) and lead 2 primer (5'-GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT-3') (SEQ ID NO:04) domains employed by Illumina®-based sequencing platforms. Other exemplary nucleic acid domains include the A adaptor (5'-CCATCTCATCCCTGCGTGTCTCCGACTCAG-3') (SEQ ID NO:05) and P1 adaptor (5'-CCTCTCTATGGGCAGTCGGTGAT-3') (SEQ ID NO:06) domains employed in Ion Torrent™ based sequencing platforms. The nucleotide sequences of nucleic acid domains useful for sequencing on a subject sequencing platform may change and / or mutate over time. Adapter sequences are typically provided by the sequencing platform manufacturer (e.g., in technical documentation provided with the sequencing system and / or available on the manufacturer's website). Based on such information, the sequence of any sequencing platform adaptor domain of a template switch oligonucleotide, first strand cDNA primer, amplification primer and / or the like can be designed to include all or a portion of one or more nucleic acid domains in a configuration that allows sequencing of a nucleic acid insert (corresponding to a template RNA) on a subject platform.

[0030] A cDNA synthesis primer may contain one or more nucleotides (or analogs thereof) that are modified or otherwise not naturally occurring. For example, a primer may contain one or more nucleotide analogs (e.g., LNA, FANA, 2'-O-Me RNA, 2'-fluoro RNA, etc.), linkage modifications (e.g., phosphorothioate, 3'-3' and 5'-5' reverse linkages), 5' and / or 3' end modifications (e.g., 5' and / or 3' amino, biotin, DIG, phosphate, thiol, dyes, quenchers, etc.), one or more fluorescently labeled nucleotides, or any other feature that provides the primer with the desired functionality for priming cDNA synthesis.

[0031] In embodiments, it may be desirable to prevent any subsequent extension reaction using the double-stranded product nucleic acid as a template from extending beyond a particular position within the region of the double-stranded product nucleic acid corresponding to the primer. For example, according to certain embodiments, the first strand cDNA primer contains a polymerase blocking modification that prevents a polymerase using the region corresponding to the primer as a template from polymerizing the nascent strand beyond the modification. Useful modifications include, but are not limited to, abasic lesions (e.g., tetrahydrofuran derivatives), nucleotide adducts, isonucleotide bases (e.g., isocytosine, isoguanine and / or the like), and any combination thereof. Such blocking modifications may be included in any of the nucleic acid reagents used in carrying out the methods of the present disclosure, including first strand cDNA primers, template switch oligonucleotides, first and second amplification, e.g., PCR, primers used in amplifying the first strand cDNA to generate the product double-stranded cDNA, amplification primers used in PCR amplification of the tagged product, and any combination thereof. In some cases, primers used in the methods of the present disclosure, such as amplification, e.g., PCR, primers, contain a ligation block. Optional ligation blocks of interest that may be present in a given primer include, but are not limited to, amine, inverted T, and biotin-TEG.

[0032] "Template switch oligonucleotide" refers to an oligonucleotide template to which a polymerase switches from an initial template (e.g., template RNA) during a nucleic acid polymerization reaction. In this regard, the template RNA may be referred to as the "donor template" and the template switch oligonucleotide may be referred to as the "acceptor template." As used herein, "oligonucleotide" may refer to a single-stranded multimer of nucleotides of 2 to 500 nt, e.g., 2 to 200 nt. Oligonucleotides may be synthetic or enzymatically generated, and in some embodiments are 10 to 50 nt in length. Oligonucleotides may include ribonucleotide monomers (i.e., may be oligoribonucleotides or "RNA oligonucleotides") or deoxyribonucleotide monomers (i.e., may be oligodeoxyribonucleotides or "DNA oligonucleotides"). The oligonucleotides can be, for example, 10-20 nt, 21-30 nt, 31-40 nt, 41-50 nt, 51-60 nt, 61-70 nt, 71-80 nt, 80-100 nt, 100-150 nt, or 150-200 nt, up to 500 nt or more in length. If employed, in some cases, the template switch oligonucleotide can be added to the reaction mixture at a final concentration of 0.01 to 100 μM, e.g., 0.1 to 10 μM, e.g., 0.5 to 5 μM, including 2 to 3 μM.

[0033] The template switch oligonucleotide may include one or more nts (or analogs thereof) that are modified or otherwise not naturally occurring. For example, the template switch oligonucleotide may include one or more nucleotide analogs (e.g., LNA, FANA, 2'-O-Me RNA, 2'-fluoro RNA, etc.), linkage modifications (e.g., phosphorothioate, 3'-3' and 5'-5' reverse linkages), 5' and / or 3' end modifications (e.g., 5' and / or 3' amino, biotin, DIG, phosphate, thiol, dyes, quenchers, etc.), one or more fluorescently labeled nts, or any other feature that provides a desired function to the template switch oligonucleotide. Any desired nucleotide analogs, linkage modifications and / or end modifications may be included in any of the nucleic acid reagents used in practicing the methods of the present disclosure.

[0034] The template switch oligonucleotide may comprise a 3' hybridization domain and a 5' amplification primer site. The 3' hybridization domain may vary in length, in some cases ranging from 2 to 10 nt in length, such as 3 to 7 nt in length. The sequence of the 3' hybridization domain, i.e., template switch domain, may be any convenient sequence, such as any sequence, a heteropolymeric sequence (e.g., a heterotrinucleotide) or a homopolymeric sequence (e.g., a homotrinucleotide such as GGG). Examples of 3' hybridization domains and template switch oligonucleotides are further described in U.S. Pat. No. 5,962,272 and published PCT application publication number WO2015027135, the disclosures of which are incorporated herein by reference.

[0035] According to certain embodiments, the template switch oligonucleotide includes a modification that prevents the polymerase from switching from the template switch oligonucleotide to a different template nucleic acid after synthesizing the complement of the 5' end of the template switch oligonucleotide (e.g., the 5' adapter sequence of the template switch oligonucleotide). Useful modifications include, but are not limited to, abasic lesions (e.g., tetrahydrofuran derivatives), nucleotide adducts, isonucleotide bases (e.g., isocytosine, isoguanine, and / or the like), and any combination thereof.

[0036] In addition to the above components, the template switch oligonucleotide may further comprise several additional components or domains located between the 5' and 3' domains described above, such as, but not limited to, a barcode domain, a unique molecular identifier domain, a sequencing platform adaptor assembly domain, and these domains may be as described above.

[0037] Fragmentation refers to any protocol in which nucleic acid molecules are broken down into shorter fragments. Fragmentation protocols include, but are not limited to, one or more transfers of the RNA sample through a micropipette tip or fine gauge needle, spraying the sample, sonicating the sample (e.g., using a focused sonicator by Covaris, Inc. (Woburn, MA)), bead-mediated shearing, enzymatic shearing (e.g., using one or more RNA shearing enzymes or by enzymatic digestion, e.g., by restriction enzymes or other endonucleases appropriate for the polynucleotide of interest), chemical-based fragmentation, e.g., using divalent cations, fragmentation buffers (which may be used in combination with heat), or any other suitable approach to shear / fragment precursor RNA to generate shorter template RNA. In certain embodiments, the nucleic acid fragments generated by fragmentation of the starting nucleic acid sample have a length of 10-20 nt, 20-30 nt, 30-40 nt, 40-50 nt, 50-60 nt, 60-70 nt, 70-80 nt, 80-90 nt, 90-100 nt, 100-150 nt, 150-200 nt, or 200-250 nt, or even 200-1000 nt or 1000-10,000 nt, depending on, for example, the sequencing platform selected.

[0038] In some cases, fragmentation includes tagging, i.e., transposome-mediated fragmentation. In transposome-mediated fragmentation (tagging), transposomes are prepared with DNA and later cleaved, so that the transposition event generates fragmented DNA with adapters (rather than insertions). The transposomes employed in the disclosed method include a transposase and a transposon nucleic acid, which may include a transposon terminal domain among other domains. Any domains are functionally defined, and therefore may be in the same sequence or different sequences as needed. Domains may also overlap.

[0039] "Transposase" refers to an enzyme that can form a functional complex with a transposon end domain-containing composition (e.g., a transposon, a transposon end, a transposon end composition) and catalyze the insertion or transposition of the transposon end-containing composition into a double-stranded target DNA in which it is incubated in an in vitro transposition reaction. Transposases that find use in carrying out the methods of the present disclosure include, but are not limited to, Tn5 transposase, Tn7 transposase, and Mu transposase. The transposase can be a wild-type transposase. In other embodiments, the transposase includes one or more modifications (e.g., amino acid substitutions) to improve the properties of the transposase, e.g., to enhance the activity of the transposase. For example, high activity mutants of Tn5 transposase (e.g., E54K, M56A, and L372P) with substitution mutations in the Tn5 protein have been developed and are described, for example, in Picelli et al. (2013) Genome Research 24:2033-2040. Additional Tn5 substitution mutations include, but are not limited to, Y41H; T47P; E54V, E110K, P242A, E344A, and E345A. A given Tn5 mutant may contain one or more substitutions, and possible combinations of substitutions include, but are not limited to, T47P, M56A, and L372P; TT47P, M56A, P242A, and L372P; and M56A, E344A, and L372P.

[0040] The term "transposon end domain" refers to double-stranded DNA that contains the nucleotide sequence ("transposon end sequence") necessary to form a complex with a transposase or integrase enzyme that functions in an in vitro transposition reaction. The transposon end domain forms a "complex" or "synaptic complex" or "transposome complex" or "transposome composition" with a transposase or integrase that recognizes and binds to the transposon end domain, allowing the complex to insert or transfer the transposon end domain into a target DNA with which it is incubated in an in vitro transposition reaction. The transposon end domain exhibits two complementary sequences consisting of a "transferred transposon end sequence" or "transferred strand" and a "non-transferred transposon end sequence" or "non-transferred strand". For example, one transposon end domain that forms a complex with a hyperactive Tn5 transposase (e.g., EZ-Tn5 transposase, EPICENTRE Biotechnologies, Madison, Wis., USA) that is active in an in vitro transposition reaction includes a transferred strand that exhibits a "transferred transposon end sequence" such as 5'AGATGTGTATAAGAGACAG3' (SEQ ID NO:07) and a non-transferred strand that exhibits a "non-transferred transposon end sequence" such as 5'CTGTCTCTTATACACATCT3' (SEQ ID NO:8). The 3' end of the transferred strand is bound or transferred to the target DNA in an in vitro transposition reaction. The non-transferred strand that exhibits a transposon end sequence that is complementary to the transferred transposon end sequence is not bound or transferred to the target DNA in an in vitro transposition reaction. The sequence of the particular transposon end domain employed in carrying out the methods of the present disclosure will vary depending on the particular transposase employed. For example, a Tn5 transposon terminal domain can be included in the transposon nucleic acid when used in combination with a Tn5 transposase.

[0041] In addition to the transposon end domain, the transposon nucleic acid may also include one or more additional domains, such as a post-tagging amplification primer site. In some cases, the post-tagging amplification primer site includes a sequencing platform adaptor construct domain, for example, as described above. This domain may be a nucleic acid domain selected from a domain (e.g., a "capture site" or "capture sequence") that specifically binds to a sequencing platform oligonucleotide attached to a surface (e.g., a P5 or P7 oligonucleotide attached to the surface of a flow cell of an Illumina® sequencing system), a sequencing primer binding domain (e.g., a domain to which the read 1 or read 2 primer of the Illumina® platform can bind), a barcode domain (e.g., a domain that uniquely identifies the sample source of the nucleic acid to be sequenced to enable multiplexing of samples by marking all molecules from a given sample with a specific barcode or "tag"), a barcode sequencing primer binding domain (a domain to which the primer used for sequencing the barcode binds), a molecular identification domain, or any combination of such domains.

[0042] When it is desired to prepare transposomes for the tagging step, any suitable transposome preparation approach may be used, and such approaches may vary, for example, depending on the particular transposase and transposon nucleic acid employed.For example, the transposon nucleic acid and the transposase may be incubated together in a suitable buffer at a suitable molar ratio (e.g., 2:1 molar ratio, 1:1 molar ratio, 1:2 molar ratio, etc.).According to one embodiment, when the transposase is a Tn5 transposase, the preparation of the transposome may include incubating the transposase and the transposon nucleic acid in a 1:1 molar ratio in 2xTn5 dialysis buffer for a sufficient time, for example, 1 hour.

[0043] Tagging includes contacting the double-stranded nucleic acid with a transposome under tagging conditions. Such conditions may vary depending on the particular transposase employed. In some cases, the conditions include incubating the transposome and tagged extension products in a buffered reaction mixture (e.g., a reaction mixture buffered with Tris acetate, etc.) at pH 7 to 8, such as pH 7.5. The transposome may be provided such that there is about one molar equivalent or molar excess of transposon compared to the tagged extension products. Suitable temperatures include 32°C to 42°C, such as 37°C. The reaction is allowed to proceed for a sufficient period of time, such as 5 minutes to 3 hours. The reaction may be terminated by adding a solution (e.g., a "stop" solution), which may contain an appropriate amount of SDS and / or other transposase reaction termination reagents to terminate the reaction. Protocols and materials for achieving nucleic acid fragmentation using transposomes are available, including, for example, those provided in the EZ-Tn5™ Transposition Kit available from EPICENTRE Biotechnologies (Madison, Wis., USA).

[0044] In some aspects of the invention, the method includes a step of obtaining single cells. The obtaining of single cells can be performed according to any convenient protocol. The single cell suspension can be obtained using standard methods known in the art, including, for example, enzymatically using trypsin or papain to digest proteins connecting cells in a tissue sample, releasing adherent cells in culture, or mechanically separating cells in the sample. The single cells can be placed in any suitable reaction vessel that allows single cells to be processed individually. For example, a 96-well plate, a 384-well plate, or a plate with any number of wells, such as 2000, 4000, 6000, 10000 or more. The multi-well plate can be part of a chip and / or device. The present disclosure is not limited by the number of wells in a multi-well plate. In various embodiments, the total number of wells on the plate is 100 to 200,000, or 5000 to 10,000. In other embodiments, the plate includes smaller chips, each containing 5000 to 20,000 wells. For example, a square chip may contain 125x125 nanowells with a diameter of 0.1 mm. The wells (e.g., nanowells) of a multiwell plate may be fabricated in any convenient size, shape, or volume. The wells may be 100 μm to 1 mm in length, 100 μm to 1 mm in width, and 100 μm to 1 mm in depth. In various embodiments, each nanowell has an aspect ratio (ratio of depth to width) of 1 to 4. In one embodiment, each nanowell has an aspect ratio of 2. The lateral cross-sectional area may be circular, elliptical, oval, conical, rectangular, triangular, polyhedral, or any other shape. The lateral area at any given depth of the well may also vary in size and shape. In certain embodiments, the wells have a volume of 0.1 nl to 1 μl. The nanowells may have a volume of 1 μl or less, such as 500 nl or less. The volume can be 200 nl or less, such as 100 nl or less. In one embodiment, the volume of the nanowell is 100 nl.If desired, nanowells can be fabricated to increase the surface area to volume ratio, thereby facilitating heat transfer through the unit and reducing the ramp time of thermal cycling. The cavity of each well (e.g., nanowell) can take on a variety of configurations. For example, the cavity within the well can be divided by straight or curved walls to form separate but adjacent compartments, or by circular walls to form inner and outer annular compartments. The wells can be designed such that a single well contains a single cell. Individual cells can also be isolated in any other suitable container, such as microfluidic chambers, droplets, nanowells, tubes, etc. Any convenient method for manipulating single cells can be employed, including fluorescence activated cell sorting (FACS), robotic device injection, gravity flow, or micromanipulation, and the use of semi-automated cell pickers (e.g., Stoelting Co.'s Quixell™ Cell Transfer System). In some cases, single cells can be deposited in wells of a plate according to Poisson statistics (e.g., such that about 10%, 20%, 30%, or 40% or more of the wells contain single cells, but the number can be defined by adjusting the number of cells in a given unit volume of fluid dispensed into the vessel). In some cases, a suitable reaction vessel contains a droplet (e.g., a microdroplet). Individual cells can be individually selected based on characteristics detectable by microscopy, such as, for example, location, morphology, reporter gene expression, antibody labeling, FISH, intracellular RNA labeling, or qPCR.

[0045] After obtaining single cells, for example as described above, the mRNA can be released from the cells by lysing the cells. Lysis can be achieved, for example, by heating or freeze-thawing the cells, or by the use of detergents or other chemical methods, or by a combination of these. However, any suitable lysis method can be used. A gentle lysis procedure can be advantageously used to prevent the release of nuclear chromatin, thereby avoiding genomic contamination of the cDNA library and minimizing degradation of the mRNA. For example, heating the cells at 72oC for 2 minutes in the presence of Tween-20 is sufficient to lyse the cells, but without detectable genomic contamination from the nuclear chromatin. Alternatively, the cells can be heated in water at 65oC for 10 minutes (Esumi et al., Neurosci Res 60(4):439-51(2008)); or in PCR buffer II (Applied Biosystems) supplemented with 0.5% NP-40 at 70oC for 90 seconds (Kurimoto et al., Nucleic Acids Res 34(5):e42(2006)). Alternatively, lysis can be achieved using a protease such as proteinase K, or by using a chaotropic salt such as guanidine isothiocyanate (US Publication No. 2007 / 0281313).

[0046] In certain embodiments of the methods described herein, cells are obtained from a tissue of interest, resulting in a single cell suspension. The single cells are placed in one well of a multi-well plate, or other suitable container, such as a microfluidic chamber or tube. The cells are lysed, and a reverse transcription reaction mix is ​​added directly to the lysate without additional purification. Once the cells are lysed, the container vessel may also contain reverse transcription reagents. The NGS library generated according to the methods disclosed herein may exhibit a desired complexity (e.g., high complexity). The "complexity" of an NGS library is related to the proportion of extra sequencing reads (e.g., sharing the same start site) obtained when sequencing the library. Complexity is inversely related to the proportion of extra sequencing reads. In a low complexity library, certain target sequences are overrepresented, while other targets (e.g., mRNAs expressed at low levels) have little or no coverage. In a high complexity library, the sequencing reads more closely track the known distribution of target nucleic acids in the starting nucleic acid sample, for example, including coverage for targets known to be present at relatively low levels in the starting sample (e.g., mRNAs expressed at low levels). According to certain embodiments, the complexity of the NGS library generated according to the method of the present disclosure is such that the sequencing reads are generated for 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more of the different species of target nucleic acids (e.g., mRNAs of different species) in the starting nucleic acid sample (e.g., RNA sample). The complexity of the library can be determined by mapping the sequencing reads to a reference genome or transcriptome (e.g., for a particular cell type). Certain approaches have been developed for determining the complexity of a sequencing library, including those described in Daley et al. (2013) Nature Methods 10(4):325-327.

[0047] In certain embodiments, the method of the present disclosure further comprises subjecting the NGS library to an NGS protocol. The protocol can be carried out on any suitable NGS sequencing platform. NGS sequencing platforms of interest include, but are not limited to, sequencing platforms provided by Illumina® (e.g., HiSeq™, MiSeq™, and / or NextSeq™ sequencing systems); Ion Torrent™ (e.g., Ion PGM™ and / or Ion Proton™ sequencing systems); Pacific Biosciences (e.g., PACBIO RS II Sequel sequencing systems); Life Technologies™ (e.g., SOLiD sequencing systems); Roche (e.g., 454 GS FLX+ and / or GS Junior sequencing systems); or any other sequencing platform of interest. NGS protocols vary according to the specific NGS sequencing system employed. For example, detailed protocols for sequencing NGS libraries, which may include further amplification (e.g., solid-phase amplification), sequencing of the amplicons, and analysis of the sequencing data, are available from the manufacturer of the NGS sequencing system employed.

[0048] In certain embodiments, the subject methods can be used to generate NGS libraries corresponding to mRNAs for downstream sequencing on a sequencing platform of interest (e.g., sequencing platforms provided by Illumina®, Ion Torrent™, Pacific Biosciences, Life Technologies™, Roche, etc.). According to certain embodiments, the subject methods can be used to generate NGS libraries corresponding to non-polyadenylated RNAs for downstream sequencing on a sequencing platform of interest. For example, microRNAs can be polyadenylated and used as templates in template-switch polymerization reactions, as described elsewhere herein. Random or gene-specific priming can also be used, depending on the researcher's goals. The library can be mixed 50:50 with a control library (e.g., Illumina®'s PhiX control library) and sequenced on a sequencing platform (e.g., an Illumina® sequencing system). The control library sequences can be removed and the remaining sequences can be mapped to the transcriptome of the source of the mRNA (e.g., human, mouse, or any other mRNA source).

[0049] Before the present invention is described in more detail, it is to be understood that the invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0050] Where a range of values ​​is provided, unless the context clearly dictates otherwise, each intervening value between the upper and lower limits of that range, to the tenth of the unit of the lower limit, and any otherwise stated or intervening value in that stated range, is included in the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also included in the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both limits, ranges excluding either or both of those included limits are also included in the invention.

[0051] In this specification, a certain range is described, and the numerical value is preceded by the term "about". The term "about" is used in this specification to provide literal support for the exact number it precedes, as well as a number that is close to or approximately the number it precedes. When determining whether a number is close to or approximately equal to a specifically stated number, the unstated number that is close or approximate may be a number that, in the context in which it is presented, results in a substantial equivalence to the specifically stated number.

[0052] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative exemplary methods and materials are described herein.

[0053] All publications and patents cited in this specification are incorporated herein by reference as if each individual publication or patent was specifically and individually indicated to be incorporated by reference, and are incorporated herein by reference to describe or describe the methods and / or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the publication dates provided may be different from the actual publication dates which may need to be independently confirmed.

[0054] It should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. It should be further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as a prior basis for using exclusive terminology such as "solely," "only," or "negative" limitations in connection with the recitation of claim elements.

[0055] As will be apparent to those skilled in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has distinct components and features which may be readily separated or combined with the features of any of the other several embodiments without departing from the scope or spirit of the invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.

[0056] Although the apparatus and methods have been described or will be described for grammatical fluidity with functional descriptions, unless expressly formulated under 35 U.S.C. § 112, the claims should not be construed as necessarily limited in any way by means- or step-limitation constructions, but should be given the full scope of meaning and equivalents of the definitions provided by the claims under the doctrine of equivalents, and where a claim is expressly formulated under 35 U.S.C. § 112, it should be expressly understood that the full statutory equivalents under 35 U.S.C. § 112 are accorded.

[0057] The present invention relates generally to complementary deoxyribonucleic acid (cDNA) synthesis, in particular to methods and kits for preparing cDNA suitable for sequencing.

[0058] The embodiments of the present invention prepare cDNA molecules suitable for sequencing, and in some cases useful in single-cell ribonucleic acid sequencing (scRNA-seq) methods. In clear contrast to the prior art scRNA-seq methods, the embodiments of the present invention achieve the advantages of both major methods, namely, they are compatible with unique molecular identifiers (UMIs) used to remove biased amplification effects, thereby allowing counting of RNA molecules present before amplification, provide full-length transcript coverage, and capture a large fraction of RNA molecules present in cells. The second major method of the prior art, including Smart-seq and Smart-seq2, provides the most sensitive information of single-cell transcriptomes, but cannot be used to count RNA molecules in single cells, since it is not compatible with UMIs.

[0059] Thus, embodiments of the present invention allow for simultaneous RNA molecule counting and full-length coverage of the transcriptome in a single cell. Importantly, embodiments of the present invention can be used to generate single-cell cDNA containing both UMIs for RNA molecule counting, as well as full transcript read coverage. Embodiments of the present invention also allow paired-end sequencing of both internal and 5'-end fragments, thus allowing better mapping of fragments and more detailed assessment of the structure of the template RNA from which the fragments are derived, such as transcript isoforms, SNP phasing, etc. Embodiments of the present invention further allow for biochemical fine-tuning of the percentage of UMI-containing 5' reads in the final sequencing library. This capability makes embodiments of the present invention, also referred to herein as smartseq3, not only the most sensitive method to date, but also flexible and adaptable to different experimental needs.

[0060] In an embodiment, the method is based on hybridization of an oligo-dT with a primer site, such as a reverse amplification primer site, to the polyA tail of an RNA molecule, for example, the mRNA of an RNA sample. A reverse transcriptase (RT) enzyme polymerizes the cDNA using the full length of the RNA molecule as a template. When the RT reaches the end of the RNA molecule, it preferably still continues the polymerization without any template by adding a few nucleotides to the 3' end of the cDNA strand. A template switching oligonucleotide (TSO), which contains a partial TN5 motif primer site, a novel identification tag, a UMI, and another primer site, such as three rGs, hybridizes to the non-templated nucleotides at the 3' end of the cDNA strand. The RT continues polymerization using the TSO as a new template to obtain an extended cDNA strand with respective primer sites at both ends. In some embodiments, the use of additional free ribonucleotides, dCTP or PEG, allows for an increase in the efficiency of the template switching reaction with respect to the captured gene.

[0061] In an embodiment, the extended cDNA strand is amplified using two primers in a PCR reaction, and the amplified product is optionally fragmented using, for example, the ILLUMINA® Nextera XT kit, which is prepared for sequencing by the ILLUMINA® platform. The identification tag and UMI in the TSO are designed to be read by the ILLUMINA® sequencer, independent of the tagging and fragmentation reaction in the ILLUMINA® Nextera kit. Thus, after sequencing, the reads belonging to the 5' end of the RNA molecule can be captured by the recognition of the identification tag and quantified based on the UMI to calculate the number of unique RNA molecules observed. At the same time, the remaining internal reads can be used to map full-length transcript features, including exons, introns, and genetic variations within the transcribed portion of the genome.

[0062] The present invention has the unique ability to combine UMI-based RNA counting with full-length transcript coverage and paired-end sequencing. The experimental data presented herein demonstrate that the present invention provides the most sensitive profiling of RNA molecules from single cells, i.e., the generated sequencing libraries contain fragments from a larger fraction of RNA in cells than all previous methods.

[0063] The present invention uses template switching oligonucleotides (TSOs) that allow the construction of 5'-tagged and full-length RNA fragments within the same sequencing library. The TSOs are designed to contain a primer site for PCR amplification, a unique identification tag that can distinguish 5' reads from a complex mixture, a UMI, and multiple predefined nucleotides such as three rGs for annealing to extended non-template bases on the cDNA strand.

[0064] Thus, one aspect of the present invention relates to a method for preparing cDNA, with reference to Figure 8. The method includes, in step S1, hybridizing a cDNA synthesis primer to an RNA molecule and synthesizing a cDNA strand complementary to at least a portion of the RNA molecule to form an RNA-cDNA intermediate, sometimes also referred to as an RNA-cDNA duplex. The method also includes step S2, which includes performing a template switching reaction using a template switching oligonucleotide (TSO) as a template by contacting the RNA-cDNA intermediate with the TSO under conditions suitable for extending the cDNA strand to form an extended cDNA strand. The extended cDNA strand is complementary to at least a portion of the RNA molecule and the TSO. According to the present invention, the TSO includes an amplification primer site, an identification tag, a UMI, and a plurality of predefined nucleotides.

[0065] The two steps S1 and S2 in Figure 8 may be performed consecutively, i.e., step S1 followed by step S2. In such a case, TSO is added to the reaction mixture from step S1 in step S2. However, alternatively, it is also possible to perform the two steps S1 and S2 together in a single reaction step. In such a case, TSO and a cDNA synthesis primer are present in the reaction mixture together with the RNA molecules to synthesize a cDNA strand to form an RNA-cDNA intermediate and to extend the cDNA strand into an extended cDNA strand.

[0066] Thus, the product of method steps S1 and S2 shown in Figure 8 is an extended cDNA strand. This extended cDNA strand is complementary to at least a portion of an RNA molecule, such as a complete RNA molecule, and is also complementary to a TSO. This means that the extended cDNA strand comprises a DNA sequence complementary to at least a portion of an RNA molecule and a DNA sequence complementary to the TSO. This latter complementary DNA sequence thus comprises a first subsequence complementary to the amplification primer site of the TSO, a second subsequence complementary to the identification tag, a third subsequence complementary to the UMI, and a fourth subsequence complementary to multiple, i.e., more than one, predefined nucleotides.

[0067] In an embodiment, step S1 of Figure 8 includes hybridizing a cDNA synthesis primer to an RNA molecule and synthesizing a cDNA strand by reverse transcription to form an RNA-cDNA intermediate. In this embodiment, step S2 includes performing a template switching reaction by contacting the RNA-cDNA intermediate with TSO under conditions suitable for elongating the cDNA strand by reverse transcription to form an extended cDNA strand.

[0068] Thus, reverse transcription is preferably used to synthesize a cDNA strand in step S1 and to extend the cDNA strand into an extended cDNA strand in step S2. In embodiments, the same reverse transcriptase may be used in the reverse transcription reaction of step S1 as in step S2. However, it is also possible to use a first reverse transcriptase in step S1 and a second reverse transcriptase in step S2.

[0069] As outlined above, illustrative but non-limiting examples of reverse transcriptases that can be used according to the embodiments include Human Immunodeficiency Virus Type 1 (HIV-1) reverse transcriptase, Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase, Avian Myeloblastosis Virus (AMV) reverse transcriptase, Telomerase reverse transcriptase, and mutant or engineered versions thereof. For example, the reverse transcriptase is preferably M-MLV reverse transcriptase, and more preferably selected from the group consisting of SuperScript™ II reverse transcriptase, SuperScript™ III reverse transcriptase, SuperScript™ IV reverse transcriptase, RevertAid H Minus reverse transcriptase, ProtoScript® II reverse transcriptase, Maxima H Minus reverse transcriptase, and EpiScript™ reverse transcriptase. In certain embodiments, the reverse transcriptase used in steps S1 and S2 is Maxima H Minus reverse transcriptase. Maxima H Minus reverse transcriptase is thermostable and has high processivity. This particular reverse transcriptase therefore allows reverse transcription to be carried out at higher temperatures, ie, 37° C. or higher, during shorter reaction times.

[0070] In an embodiment, the reverse transcription in steps S1 and S2 is performed in the presence of ribonucleotides, including guanine ribonucleotides. In such an embodiment, the ribonucleotides are present at a concentration selected within the interval of 0.05 mM to 10 mM, preferably within the interval of 0.1 mM to 3 mM, such as about 1 mM. The addition of complementary ribonucleotides to the template switching reaction promotes a longer and more stable non-templated C-tail in the context of M-MLV reverse transcriptase when the reverse transcriptase reaches the 5' end of the RNA molecule that serves as the template. Such complementary ribonucleotides can also be used to fine-tune the efficiency of the template switching reaction. The experimental data presented herein show that the addition of guanine ribonucleotides can be used to control gene capture and the fraction of 5' reads in the resulting sequencing library.

[0071] In an embodiment, reverse transcription is carried out in the presence of a mixture of dATP, dGTP, dTTP and dCTP. The mixture preferably contains the same concentration of dATP, dGTP and dTTP, and the concentration of dCTP is XmM higher than the same concentration of dATP, dGTP and dTTP. Thus, if the concentration of each of dATP, dGTP and dTTP in the mixture is YmM, the concentration of dCTP in the mixture is preferably X+YmM. In an embodiment, X is selected within the interval of 0.05mM to 10mM, preferably within the interval of 0.1mM to 3mM, such as about 1mM. In an embodiment, Y is selected within the interval of 0.05mM to 10mM, preferably within the interval of 0.1mM to 3mM, such as about 0.5mM.

[0072] Deoxynucleotides (dNTPs) are used in reverse transcription to synthesize and extend the cDNA strand. Additional dCTP is preferably added to the reverse transcription and template switching reaction to increase the incorporation of C into the non-templated stretch of nucleotides at the 3' end of the cDNA strand. Thus, the 3' end of the synthesized cDNA strand preferably contains a stretch of C, as shown diagrammatically in FIG. 1A. In such a case, the plurality of predefined nucleotides are preferably guanine nucleotides, such as guanine ribonucleotides (rG), guanine deoxynucleotides (dG), locked nucleic acid (LNA) guanine (LNA-G), 2'-fluoro-guanine (fG) and any combination thereof. Thus, the plurality of predefined nucleotides of the TSO are preferably complementary to the non-templated stretch of nucleotides added to the 3' end of the cDNA strand in the reverse transcription performed in step S1.

[0073] The specific ribonucleotide present in the reverse transcription is preferably the same nucleobase as the multiple predefined nucleotides of TSO. Furthermore, the additional nucleotide present in the reverse transcription is preferably complementary to this nucleobase. This means that combinations of nucleobases other than G and C can be used. For example, the multiple predefined nucleotides can be multiple guanine nucleotides, multiple cytosine nucleotides, multiple adenine nucleotides, or multiple thymidine nucleotides. The added ribonucleotides are then guanine ribonucleotides, cytosine ribonucleotides, adenine ribonucleotides or uracil ribonucleotides, and the additional nucleotides are dCTP, dGTP, dTTP or dATP.

[0074] In an embodiment, reverse transcription is carried out in the presence of magnesium salt at a concentration selected within the interval of 0.1 mM to 20 mM, preferably within the interval of 1 mM to 10 mM, more preferably within the interval of 2 mM to 5 mM, such as about 3 mM. In an embodiment, the magnesium salt is selected from the group consisting of MgCl2, MgOAc and MgSO2. In a preferred embodiment, the magnesium salt is MgCl2. A relatively low concentration of magnesium salt in reverse transcription reduces the fidelity of reverse transcriptase.

[0075] In an embodiment, reverse transcription is carried out in the presence of a chloride salt selected from the group consisting of sodium chloride (NaCl), cesium chloride (CsCl), and mixtures thereof. The chloride salt is present at a concentration selected preferably within the interval of 5 mM to 500 mM, preferably within the interval of 15 mM to 250 mM, more preferably within the interval of 50 mM to 100 mM, or 25 mM to 150 mM, such as about 75 mM.

[0076] In an embodiment, reverse transcription is performed in the absence, or at least reduced amounts, of potassium chloride (KCl). KCl promotes a four-stranded structure of RNA molecules when there is a stretch of rG nucleotides, either intramolecularly or intermolecularly. This structure is called a G-quadruplex and inhibits reverse transcription. The use of chloride salts other than KCl may improve reverse transcription and reduce the appearance of G-quadruplex RNA secondary structures. Both NaCl and CsCl result in higher reverse transcription efficiency compared to KCl with Maxima H Minus reverse transcriptase.

[0077] In embodiments, at least one reverse transcription and / or amplification enhancer is added to facilitate the enzymatic kinetics of the reverse transcription and / or amplification reaction. Non-limiting but illustrative examples of such enhancers include betaine, bovine serum albumin (BSA), glycerol, polyethylene glycol (PEG), glycogen, 1,2-propanediol, dimethylsulfoxide (DMSO), dimethylformamide (DMF), polyoxyethylene sorbitan monolaurate such as polysorbate 20, polysorbate 40 and / or polysorbate 80, T4 gene 32 protein and dithiothreitol (DTT).

[0078] In an embodiment, reverse transcription is carried out in the presence of PEG with an average molecular weight selected within the interval of 300Da to 100,000Da, preferably within the interval of 1,000Da to 25,000Da, more preferably within the interval of 7,000Da to 9,000Da, such as 8000Da. PEG, such as PEG 8000, acts as a crowding agent and reduces the effective reaction volume. This increases the enzyme reaction rate. Therefore, adding PEG can improve the sensitivity of the method.

[0079] In some embodiments, the TSO comprises, from the 5' end to the 3' end, an amplification primer site, an identification tag, a UMI, and a number of predefined nucleotides. In some embodiments, the identification tag can function as an amplification primer site, such that the TSO comprises a new identification tag, a UMI, and a number of predefined nucleotides (i.e., the identification is employed as both an identification tag and an amplification primer site). In such cases, the TSO does not comprise a separate amplification primer site. Thus, in some cases, the TSO comprises a unique identification tag, a UMI, and a number of predefined nucleotides, such as three rGs, that can identify the 5' read from a complex mixture, and the unique identification tag also functions as a primer site for PCR amplification.

[0080] In embodiments, the amplification primer site of the TSO comprises a portion of a transposase motif sequence, such as a transposase 5 (Tn5) motif sequence. The Tn5 transposase cleaves a DNA molecule and adds the following sequence to both ends of each DNA fragment: 5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3'(SEQ ID NO:9) 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-3'(SEQ ID NO:10)

[0081] Thereby, a portion of the Tn5 motif sequence constitutes a portion of either of the above two sequences. For example, the portion of the Tn5 motif sequence is preferably the 3' portion of either of the above two sequences. Thus, in an embodiment, the portion of the Tn5 motif sequence comprises, and preferably consists of, 5'-AGAGACAG-3'. This particular amplification primer site is compatible with ILLUMINA® Nextera P5 index primers.

[0082] In an embodiment, the identification tag of the TSO comprises a nucleotide sequence that does not exist in the transcriptome of the cell from which the RNA molecule originates or other RNA source.Therefore, the identification tag is unique and does not exist in the transcriptome of the source material, for example, the source cell from which the RNA molecule originates.Therefore, this common identification tag can be used to identify 5' reads from a complex mixture of nucleic acid molecules.

[0083] In an embodiment, the identification tag comprises, and preferably consists of, 5'-ATTGCGCAATG-3' (SEQ ID NO:11), which is not present in either the human or mouse transcriptome.

[0084] In an embodiment, the UMI of the TSO is a random n1n2n3...n k is an array, where n i , i=1...k is one of adenine (A), thymidine (T), cytosine (C) and guanine (G). In an embodiment, k is 4 to 12, preferably 6 to 10, such as 8. For k=8, 65,5536 unique UMIs are possible using the nucleotides A, T, C and G. UMIs function to reduce quantitative bias introduced by amplification.

[0085] In an embodiment, the plurality of predefined nucleotides of TSO are three ribonucleotides, preferably three guanine ribonucleotides, i.e. rGrGrG. In an alternative embodiment, the plurality of predefined nucleotides are ribonucleotides other than guanine ribonucleotides, such as rC, rA or rU, for example, in the case of three ribonucleotides, rCrCrC, rArArA or rUrUrU. In a further alternative embodiment, guanine nucleotides other than guanine ribonucleotides are used as the plurality of predefined nucleotides as described above. For example, at least one of the plurality of predefined nucleotides can be LNA.

[0086] In a particular embodiment, the TSO thereby comprises, and preferably consists of, the following sequence: 5'-AGAGACAGATTGCGCAATGNNNNNNNNRGrGrG-3' (SEQ ID NO:12).

[0087] In embodiments, the cDNA synthesis primer is an oligo dT primer, i.e., contains multiple dTs. In certain embodiments, the oligo dT primer is a fixed oligo dT primer.

[0088] The oligodT primer, preferably the fixed oligodT primer, is complementary to the polyA tail of the RNA molecule and can hybridize thereto. In the case of the fixed oligodT primer, the oligodT primer comprises at least one additional selective nucleotide. As is well known in the art, eukaryotic mRNA typically comprises, from the 5' end to the 3' end, a cap, a 5' untranslated region (UTR), a coding sequence (CDS), a 3'UTR and a polyA tail. This means that the fixed oligodT primer preferably comprises, in addition to the polyA tail, at least one nucleotide that is complementary to the last nucleotide(s) of the 3'UTR or, if the mRNA molecule lacks a 3'UTR, the last nucleotide(s) of the CDR.

[0089] In an embodiment, instead of being an oligo dT primer, the cDNA synthesis primer is a gene specific primer, whereby the oligo dT domain described above is replaced by a gene specific sequence, i.e., a sequence that hybridizes to a known sequence in the gene of interest.

[0090] In an embodiment, for cDNA synthesis, e.g., oligo dT, the primer comprises from the 5' end to the 3' end, a primer site, (T) p , V, and N, where V is selected from the group consisting of A, C, and G, N is selected from the group consisting of A, C, G, and T, and p is a positive number selected between 10 and 50, preferably between 15 and 45, more preferably between 20 and 40, such as 30.

[0091] In embodiments, the primer site comprises a nucleotide sequence that is not present in the transcriptome of the cell or other source from which the RNA molecule is derived. In certain embodiments, the primer site comprises, and preferably consists of, 5'-ACGAGCATCAGCAGCATACGA-3' (SEQ ID NO:13). This primer site is not present in either the human or mouse transcriptome.

[0092] In a particular embodiment, the cDNA synthesis primer has the sequence 5'-ACGAGCATCAGCAGCATACGA(T) p It comprises, and preferably consists of, VN-3' (SEQ ID NO:14).

[0093] The purpose of a fixed cDNA synthesis, e.g., oligo dT, VN of the primer is to avoid random and multiple poly-T priming at the poly-A tail. As a result, the fixed oligo dT primer binds to the 5'-end portion of the poly-A tail because it contains at least one nucleotide complementary to the 3'-end of the 3' UTR or the 3'-end of the CDS of the RNA molecule.

[0094] In an embodiment, step S1 of FIG. 8 includes, for each RNA molecule of the plurality of RNA molecules, hybridizing a cDNA synthesis primer to the RNA molecule and synthesizing a respective cDNA strand complementary to at least a portion of the RNA molecule to form a respective RNA-cDNA intermediate. In this embodiment, step S2 includes performing a template switching reaction by contacting each RNA-cDNA intermediate with each TSO under conditions suitable for extending each cDNA strand using each TSO as a template to form a respective extended cDNA strand complementary to the RNA molecule and at least a portion of the respective TSO. In this embodiment, each TSO includes an amplification primer site, an identification tag, a UMI, and a plurality of predefined nucleotides. Each TSO includes a UMI that is unique to the TSO and different from the UMIs of other TSOs. In these embodiments, the total number of TSOs with different UMIs can vary, with the collection of UMI-varying TSOs ranging from 100 to 100,000, including 100 to 250,000 in some cases, e.g., 1,000 to 75,000. The number of UMIs employed for a given sample may vary and may be selected with respect to the complexity of the sample, e.g., fewer UMIs may be employed in less complex samples and more UMIs may be employed in more complex samples.

[0095] Therefore, the present invention can be used to prepare cDNA molecules from a mixture of multiple different RNA molecules.In such a case, the same cDNA synthesis primer is preferably used, while the TSOs used have different UMIs, but preferably have the same amplification primer site, the same common identification tag and the same number of predefined nucleotides.For example, a set of 65,536 unique TSOs with different UMIs can be obtained with a UMI length of 8 nucleotides.

[0096] In an embodiment, the method also includes lysing the cells (e.g., as described above) to release the RNA molecules, as shown in FIG. 1A. The RNA molecules are preferably poly(A) containing RNA molecules, such as mRNA molecules, and are typically present in and released from the cytoplasm of the lysed cells. Any known cell lysis method can be used to release the RNA molecules from the cells. The lysis method can include the use of enzymes, detergents and / or chaotropic agents. Alternatively, or in addition, mechanical disruption of the cell membrane can be used, such as by repeated freezing and thawing and / or sonication. For example, Triton X-100 can be used as a detergent in lysing the cells.

[0097] Figure 1A illustrates the reverse transcription and template switching reactions of steps S1 and S2 of Figure 8. In an embodiment, the method also includes amplifying the extended cDNA strand using a forward primer (also referred to herein as a first forward primer or a first forward amplification primer) and a reverse primer (also referred to herein as a first reverse primer or a first reverse amplification primer), shown diagrammatically in Figure 1A as a PCR pre-amplification.

[0098] Amplification of the extended cDNA strand can be used for steps S1 and S2, i.e., sequentially after formation of the extended cDNA strand. In another embodiment, amplification of the extended cDNA strand is performed in the same reaction mixture and / or simultaneously with the reverse transcription and template switching reactions.

[0099] In an embodiment, the forward primer comprises an amplification primer site and an identifier tag. In an embodiment, the forward primer comprises, from the 5' to 3' end, a Tn5 motif sequence and an identifier tag. In a specific embodiment, the forward primer comprises, or preferably consists of, 5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGATTGCGCAATG-3' (SEQ ID NO: 15).

[0100] In an embodiment, the reverse primer comprises a primer site for cDNA synthesis, e.g., oligo dT, a primer, or at least a portion thereof. Thus, in an embodiment, the reverse primer comprises, and preferably consists of, 5'-ACGAGCATCAGCAGCATACGA-3' (SEQ ID NO:16).

[0101] The amplification step is preferably a PCR-based amplification using a polymerase such as Taq polymerase or Phu polymerase or other DNA polymerase. Non-limiting but illustrative examples of polymerases that can be used for PCR-based amplification include Phusion High Fidelity DNA polymerase, Platinum SuperFi DNA polymerase, Q5 High Fidelity DNA polymerase, KAPA HiFi HotStart DNA polymerase, and TERRA™ PCR Direct polymerase.

[0102] In embodiments, the method also includes fragmenting the resulting amplified cDNA molecules, e.g., using a fragmentation protocol as described above with reference to Figure IB, and subsequently tagging the resulting fragments, e.g., for NGS. In some cases, fragmentation and tagging of the extended cDNA strand or an amplified version thereof is accomplished in a tagging process that uses a transposase and at least one tagging adapter to form tagged cDNA fragments.

[0103] In certain embodiments, the fragmentation and tagging step comprises fragmenting and tagging the extended cDNA strand or an amplified version thereof in a tagging process using Tn5 and a first tagging adapter comprising a lead 1 sequencing primer site and an amplification primer site, and a second tagging adapter comprising a lead 2 sequencing primer site and an amplification primer site. In certain embodiments, the first tagging adapter preferably comprises, and preferably consists of, 5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3' (SEQ ID NO:17) and the second tagging adapter preferably comprises, and preferably consists of, 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-3' (SEQ ID NO:18).

[0104] A transposase (EC 2.7.7) is an enzyme that binds to the ends of a transposon and catalyzes the movement of the transposon to another part of the genome by a cut-and-paste mechanism or a replicative transposition mechanism. Tn5 is a transposase that simultaneously has tagging and fragmentation properties. Thus, in addition to tagging cDNA molecules, such transposases can further shorten the length of the cDNA molecules to achieve a length more suitable for subsequent sequencing of the cDNA molecules. Other transposases besides Tn5 can be used, including, for example, Mu transposase and Tn7 transposase.

[0105] The tagged cDNA fragment can then be amplified in the presence of a forward amplification primer (also referred to herein as a second forward primer or a second forward amplification primer) and a reverse amplification primer (also referred to herein as a second reverse primer or a second reverse amplification primer) as shown in FIG. 1B.

[0106] In an embodiment, the second forward amplification primer comprises, from the 5' to 3' end, the P5 sequence 5'-AATGATACGGCGACCACCGA-3' (SEQ ID NO:19), an i5 index, and a portion of the lead 1 sequencing primer site. In a particular embodiment, the i5 index is preferably selected from the group consisting of N501:TAGATCGC, N502:CTCTCTAT, N503:TATCCTCT, N504:AGAGTAGA, N505:GTAAGGAG, N506:ACTGCATA, N507:AAGGAGTA, and N508:CTAAGCCT. Thus, the second forward amplification primer preferably comprises or consists of the sequence 5'-AATGATACGGCGACCACCGANNNNNNNNTCGTCGGCAGCGTC-3' (SEQ ID NO:20), where NNNNNNNN represents the i5 index.

[0107] The second reverse amplification primer preferably comprises, from the 5' to 3' end, the P7 sequence 5'-CAAGCAGAAGACGGCATACGAGAT-3' (SEQ ID NO:21), an i7 index, and a portion of the read 2 sequencing primer site. In certain embodiments, the i7 index is preferably selected from the group consisting of N701:TAAGGCGA, N702:CGTACTAG, N703:AGGCAGAA, N704:TCCTGAGC, N705:GGACTCCT, N706:TAGGCATG, N707:CTCTCTAC, N708:CAGAGAGG, N709:GCTACGCT, N710:CGAGGCTG, N711:AAGAGGCA, N712:GTAGAGGA. Thus, the second reverse amplification primer preferably comprises or consists of the sequence 5'-CAAGCAGAAGACGGCATACGAGATNNNNNNNNGTCTCGTGGGCTCGG-3' (SEQ ID NO:22), where NNNNNNNN represents the i7 index.

[0108] The amplified tagged cDNA fragments can then be sequenced as shown in Figure IB by adding at least one sequencing primer, which preferably has a sequence corresponding to or complementary to at least a portion of the at least one tagging adapter.

[0109] In an embodiment, at least one sequencing primer is selected from those that can be used in ILLUMINA® sequencing technology, particularly those that can be used in ILLUMINA® sequencing technology for DNA sequences prepared with the Nextera DNA Library Preparation Kit. Examples of such sequencing primers include ILLUMINA® BP10-Lead 1 primer, ILLUMINA® BP11-Lead 2 primer, and ILLUMINA® BP14-Index 1 primer and Index 2 primer.

[0110] In an embodiment, ILLUMINA® sequencing technology can be used to sequence at least a portion of the amplified tagged cDNA fragments by synthesis. Sequencing by synthesis (SBS) uses four fluorescently labeled nucleotides to sequence the amplified tagged cDNA fragments on the flow cell surface in parallel. During each sequencing cycle, a single labeled deoxynucleoside triphosphate (dNTP) is added to the nucleic acid strand. After incorporation of each dNTP, the fluorescent dye is imaged to identify the base, and then enzymatically cleaved to allow incorporation of the next nucleotide, since the nucleotide label serves as a terminator for polymerization. More information on ILLUMINA® sequencing technology can be found in Technology Spotlight: ILLUMINA® Sequencing [9].

[0111] Another aspect of the present invention relates to a method for preparing a cDNA library, the method comprising preparing tagged cDNA fragments from RNA molecules, preferably from a single cell, as described above and shown in Figures 1A and 1B. The method also comprises adjusting the percentage of tagged cDNA fragments corresponding to the 5'-end portion of the extended cDNA strand.

[0112] Therefore, the percentage of tagged cDNA fragments corresponding to the 5'-end portion of the extended cDNA strand and containing the respective UMI and identification tag is adjusted. In other words, the ratio between the number of tagged cDNA fragments corresponding to the 5'-end portion of the extended cDNA strand and the total number of tagged cDNA fragments can be adjusted or controlled.

[0113] The experimental data presented herein (see FIG. 4) shows that tuning can be accomplished by controlling or selecting the amount of Tn5 transposase present in the fragmentation and tagging step, by controlling or selecting the amount of input cDNA in the fragmentation and tagging step, and / or by controlling or selecting the reaction time in the fragmentation and tagging step, etc. For example, the ratio of Tn5 to cDNA can be controlled or selected to control or tune tagging efficiency.

[0114] The ability to control the percentage of 5' end reads is an advantageous feature, since different applications may use different ranges of internal reads to UMI.For example, applications that utilize the high sensitivity of the present invention to quantify gene expression want to achieve the highest possible percentage of 5' end fragments, while, for example, analysis of allelic transcription requires both internal reads to capture the genetic variation between alleles combined with UMI for gene quantification.Therefore, the ability to control the percentage of 5' end reads is an advantageous feature of the present invention.

[0115] In an alternative embodiment, the balance between 5'-end fragments and internal fragments can be adjusted by amplifying the extended cDNA strand using a forward primer (also referred to herein as the first forward primer or the first forward amplification primer) and a reverse primer (also referred to herein as the first reverse primer or the first reverse amplification primer), where the forward primer contains a biotin or other capture moiety. The resulting 5'-end fragments can then be separated from the internal fragments, for example by capture of the biotin-containing fragments on streptavidin beads. Libraries for sequencing can then be prepared separately for the 5'-end fragments captured on the beads and the internal fragments that remain unbound to the beads using the methods described herein. The separate libraries can then be pooled in any suitable ratio of interest to adjust the ratio of 5'-end fragments to internal fragments.

[0116] A further aspect of the invention relates to a method for preparing a nucleic acid fragment, in an embodiment of such aspect, the method comprises hybridizing a cDNA synthesis primer to a ribonucleic acid (RNA) molecule and synthesizing a cDNA strand complementary to at least a portion of the RNA molecule to form an RNA-cDNA intermediate, e.g., as described above; performing a template switching reaction by contacting the RNA-cDNA intermediate with a template switching oligonucleotide (TSO) under conditions suitable for extending the cDNA strand using the TSO as a template, e.g., as described above, to form an extended cDNA strand complementary to the RNA molecule and at least a portion of the TSO, wherein the TSO comprises an amplification primer site, an identification tag, a unique molecular identifier (UMI), and a plurality of predefined nucleotides; generating double-stranded cDNA from the extended cDNA strand, e.g., via PCR amplification, e.g., as described above; and fragmenting the double-stranded cDNA to generate nucleic acid fragments comprising a first population of 5'UMI-containing fragments and a second population of internal fragments, e.g., as described above. If fragmentation is accomplished via tagging, the resulting first population of 5'UMI-containing fragments and the second population of internal fragments may include tagging adapters that are added to the ends of the fragments during the tagging step. If fragmentation is accomplished via other protocols, such as those described above, the method may include tagging the first population of 5'UMI-containing fragments and the second population of internal fragments with tagging adapters, such as via a ligation protocol, a non-ligation protocol, etc. The methods of these embodiments may include simultaneously generating nucleic acid fragments from multiple distinct RNAs of an RNA sample, such as the mRNA of a single cell.

[0117] In some embodiments, the second group of 5'UMI containing fragments and internal fragments obtained can be sequenced, for example, as described above.In such a case, the method can include distinguishing the sequencing reads of the first group of 5'UMI-containing fragments from the sequencing reads of internal fragments by the presence of an identification tag sequence.In other words, the reads obtained from the fragments that contain an identification tag sequence can be identified as originating from the 5'UMI-containing fragments, and the reads obtained from the fragments that lack an identification tag sequence can be identified as originating from the internal fragments.

[0118] In some embodiments, the method further comprises constructing a full-length sequence of the RNA from the sequencing reads of both the 5'UMI-containing fragment and the internal fragment. In such a case, the method may comprise pairing the 5'UMI-containing read with a first read from a first internal fragment whose 5' end aligns with the 3' end of the 5'UMI-containing read. The resulting composite read may then be paired with a second read from a second internal fragment whose 5' end aligns with the 3' end of the read from the first internal fragment. This process may continue until a complete read of the sequence of the RNA is obtained. Of course, the internal read employed in such a case is the sequencing read of the internal fragment generated from the same RNA from which the 5'UMI-containing fragment was generated.

[0119] An embodiment of the above method is shown in FIG. 19. As shown in FIG. 19, first strand cDNA is generated from the initial mRNA using a first strand primer and a TSO containing a Tn5 motif that includes a primer site, a unique tag, and a UMI, for example by performing reverse transcription and template switching as described above. Following PCR amplification, the resulting double stranded cDNA is subjected to a tagging step to generate a first population of 5'UMI-containing fragments and a second population of internal fragments. The resulting fragments are then sequenced to obtain 5'UMI reads and internal reads, all from the same RNA. The 5'UMI reads and internal reads are then aligned to build the complete sequence of the RNA. As shown in FIG. 19, not only are the 5' fragments unique due to the UMI, so that they can be used to build a transcript model using a combination of paired-end reads of these fragments with different 3' ends generated via tagging, but also because the break points of the original full-length cDNA by the transposon are themselves unique, the break points can act as additional "UMIs" and essentially link a unique set of 5' fragments to a unique set of internal reads. This feature can then be extended as well by cleaving the 3' side of this first internal fragment, so that a next set of 3' internal fragments of the first and like can be added, essentially following the transcript from the 5' end to the 3' end all the way through. As shown in Figure 19, when tagging is used to generate fragments, the tagging mechanism creates staggered cuts in the DNA, such that 9 bases at the fragmentation point are repeated in the fragment pairs coming from either side of the breakpoint. This 9-base signature can be employed in practicing the methods of the invention to help identify pairs of adjacent fragments that originally came from the same molecule.

[0120] For example, following obtaining sequencing reads as described above, the method may further include one or more additional steps of employing the sequencing reads. For example, an embodiment of the method may further include assigning an isoform to the RNA. Thus, the method may include determining which of several potential isoforms a given sequence belongs to. Thus, the method may include distinguishing between mRNAs that are generated from the same locus but differ in their transcription start sites (TSS), protein-coding DNA sequences (CDS) and / or untranslated regions (UTR).

[0121] In an embodiment, the method further comprises identifying at least a first single nucleotide polymorphism (SNP) of the RNA. In such a case, the method may comprise identifying a second or subsequent SNP of the RNA. In such a case, the method comprises establishing a topological relationship of the first and second SNPs. For example, the method of the present invention can be used to determine with certainty that two SNPs found in the same linked read are from the same original molecule. Therefore, the SNPs must, by definition, be on the same chromosome. Thus, their topological relationship to each other can be established. This capability can be employed in the assessment of inherited genetic diseases, such as cancer or other inherited genetic diseases, where one may wish to know whether a particular gene is mutated on both maternal and paternal chromosomes (i.e., generating a null homozygous mutation) or only one (heterozygous mutant / wild type). Such methods can be employed in clinical applications, such as diagnosis and / or treatment.

[0122] In embodiments, the methods include identifying the RNA as the product of a gene fusion, i.e., a hybrid gene formed from two previously separate genes, such as may be formed as a result of a translocation, interstitial deletion, or chromosomal inversion.

[0123] Method embodiments may include normalizing the population of fragments. Normalization may be considered as a process of equalizing DNA library concentrations for multiplexing, addressing the issue of over- or under-representation of libraries in a given multiplexed configuration. In a given multiplex NGS workflow, normalization may be employed at various stages, such as normalizing the concentration of input DNA / RNA, the size distribution of library fragments, as well as normalizing library preparation concentrations prior to pooling. In some cases, the normalization protocol described in PCT Application Serial No. PCT / US2019 / 064477, filed December 4, 2019, the disclosure of which is incorporated herein by reference, is employed.

[0124] A further aspect of the present invention relates to a kit for preparing cDNA. The kit comprises a cDNA synthesis primer configured to hybridize to an RNA molecule to allow synthesis of a cDNA strand complementary to at least a portion of the RNA molecule to form an RNA-cDNA intermediate. The kit also comprises an amplification primer site, an identification tag, a UMI, and a TSO comprising a plurality of predefined nucleotides.

[0125] In embodiments, the TSO is configured to act as a template in a template switching reaction that involves extension of a cDNA strand to form an extended cDNA strand complementary to an RNA molecule and at least a portion of the TSO.

[0126] In an embodiment, the kit comprises a set of TSOs that differ from each other by their UMIs, eg, as described above.

[0127] In an embodiment, the kit also comprises a reverse transcriptase, preferably selected from among the examples of reverse transcriptases given above.

[0128] In an embodiment, the kit comprises a ribonucleotide, preferably a guanine ribonucleotide, at a concentration selected within the interval of 0.05 mM to 10 mM, preferably within the interval of 0.1 mM to 3 mM.

[0129] In an embodiment, the kit comprises a mixture of dATP, dGTP, dTTP and dCTP.The mixture preferably comprises the same concentration of dATP, dGTP and dTTP, and the same concentration of dATP, dGTP and dTTP, and the concentration of dCTP is XmM higher than that of dATP, dGTP and dTTP.In an embodiment, X is selected within the interval of 0.05mM to 10mM, preferably within the interval of 0.1mM to 3mM.

[0130] In an embodiment, the kit comprises a magnesium salt at a concentration selected within the interval of 0.1 mM to 20 mM, preferably within the interval of 1 mM to 10 mM, more preferably within the interval of 2 mM to 5 mM. The magnesium salt is preferably selected from among the examples of magnesium salts given above.

[0131] In an embodiment, the kit comprises a chloride salt selected from the group consisting of NaCl, CsCl, and mixtures thereof. In an embodiment, the kit does not comprise any KCl.

[0132] In an embodiment, the kit comprises at least one reverse transcription and / or amplification enhancer.At least one such enhancer is preferably selected from among the examples of enhancers mentioned above.In an embodiment, the kit comprises PEG having an average molecular weight selected within the interval of 300Da to 100,000Da, preferably within the interval of 1,000Da to 25,000Da, more preferably within the interval of 7,000Da to 9,000Da, such as 8000Da.

[0133] In an embodiment, the kit comprises a forward primer and a reverse primer for amplifying the extended cDNA strand.

[0134] In embodiments, the kit comprises a transposase and at least one tagging adapter for fragmenting and tagging the extended cDNA strand or an amplified version thereof in a tagging process to form tagged cDNA fragments.

[0135] In embodiments, the kit includes forward and reverse amplification primers for amplifying tagged cDNA fragments.

[0136] In an embodiment, the kit comprises at least one sequencing primer, preferably having a sequence corresponding to or complementary to at least a portion of at least one tagging adapter for sequencing the amplified tagged cDNA fragments.

[0137] The kit can be advantageously used in the method for preparing cDNA according to the invention.

[0138] In addition to the above components, the subject kits may further include instructions for using the components of the kit, for example, to perform the above subject methods. Additionally, the kits may further include programming for analysis of the results, including, for example, counting unique molecular species. The instructions and / or analysis programming may be recorded on a suitable recording medium. The instructions and / or programming may be printed on a substrate, such as paper or plastic. Thus, the instructions may be present in the kit as a package insert, such as on the labeling of the kit's container or its components (i.e., associated with the packaging or subpackaging). In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer-readable storage medium, such as, for example, a CD-ROM, a diskette, a hard disk drive (HDD), etc. In still other embodiments, the actual instructions are not present in the kit, but a means is provided for obtaining the instructions from a remote source, for example, via the Internet. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and / or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.

[0139] The following examples are offered by way of illustration and not by way of limitation.

[0140] I. Example 1 A. Materials and Methods cell culture HEK293FT cells (Invitrogen) were cultured in complete Dulbecco's modified Eagle's medium (DMEM) containing glucose and glutamine (Gibco), supplemented with 10% fetal bovine serum (FBS), 0.1 mM MEM non-essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), and 100 μg / mL penicillin / streptomycin (Gibco). Cells were passaged using TrypLE express (Gibco).

[0141] Single cell isolation and lysis Single cell suspensions were prepared by dissociating HEK293FT cells using TrypLE Express that were resuspended in phosphate-buffered saline (PBS) and stained with propidium iodide (PI) to distinguish between live and dead cells. Single cells were sorted into 96- or 384-well plates using a BD FACSMelody 100 μm nozzle (BD Bioscience) containing 3 μL of lysis buffer. The lysis buffer contained 1 U / μL recombinant RNase inhibitor (RRI) (Takara), 0.15% Triton X-100 (Sigma), 0.5 mM dNTPs / each (Thermo Scientific), 1 μM Smartseq3 OligodT primer (5'-biotin-ACGAGCATCAGCAGCATACGAT 30 VN-3' (SEQ ID NO:11; IDT), and 0.05 μL of 1:40.000 diluted External RNA Control Consortium (ERCC) Spike-in Mix 1 (Ambion). Immediately after sorting, plates were spun down and stored at -80°C.

[0142] Generation of Smart-seq2 libraries Smart-seq2 cDNA libraries were generated according to published protocols [10-11]. Tagging was performed with similar cDNA inputs and volumes as Smartseq3, described below.

[0143] Reverse transcription To facilitate dissolution and denaturation of the RNA, the plate of cells was incubated at 72°C for 10 min and then immediately placed on ice. Next, 5 μL of reverse transcription mix was added to each sample, containing 50 mM Tris-HCl pH 8.3 (Sigma), 75 mM NaCl (Ambion) or CsCl (Sigma), 1 mM GTP (Thermo Scientific), 3 mM MgCl2 (Ambion), 10 mM DTT (Thermo Scientific), 5% PEG (Sigma), 1 U / μL RRI (Takara), 2 μM Smartseq3 template switching oligo (TSO) (5'-biotin-AGAGACAGATTGCGCAATGNNNNNNNNNrGrGrG-3' (SEQ ID NO:23); IDT) and 2 U / μL Maxima H-minus reverse transcriptase enzyme (Thermo Scientific). In other variations of the protocol that did not use PEG, the reverse transcription mix also contained 1 mM dCTP (Thermo Scientific). Reverse transcription and template switching was carried out at 42° C. for 90 min, followed by 10 cycles of 2 min at 50° C. and 2 min at 42° C. The reaction was stopped by incubation at 85° C. for 5 min.

[0144] PCR preamplification PCR preamplification was performed immediately after reverse transcription by adding 17 μL of PCR mix consisting of 2× KAPA HiFI HotStart Readymix (0.5 U DNA polymerase, 0.3 mM dNTPs, 2.5 mM MgCl2, 1× in 25 μL reaction) (Roche), 0.1 μM Smartseq3 forward PCR primer (5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGATTGCGCAATG-3′ (SEQ ID NO: 24); IDT), and 0.1 μM Smartseq3 reverse PCR primer (5′-ACGAGCATCAGCAGCATACGA-3′ (SEQ ID NO: 25); IDT). PCR was cycled as follows: 98°C for 3 min for initial denaturation, 20 cycles of 98°C for 20 s, 65°C for 30 s, and 72°C for 6 min. Final extension was performed at 72°C for 5 min.

[0145] Library preparation and sequencing Following PCR preamplification, all samples were purified with AMpure XP beads (Beckman Coulter) at a sample-to-beads ratio of 1:0.8. Final elution was with 15 μL of H2O (Thermo Scientific). The size distribution of the libraries was checked with a high-sensitivity DNA chip (Agilent Bioanalyzer) and cDNA was quantified using the Quant-iT PicoGreen dsDNA Assay Kit (Thermo Scientific). 200 pg of pre-amplified cDNA was used for tagmentation using the Nextera XT DNA Sample Preparation Kit (Illumina) in 1 / 5 volume according to the manufacturer's protocol. After tagmentation, samples were pooled and the pool was purified with Ampure XP beads at a ratio of 1:0.6. All libraries were sequenced at 1 × 76 bp single-end using an ILLUMINA® NextSeq500 instrument with a high-output flow cell.

[0146] Read alignment and gene expression estimation Raw non-demultiplexed fastq files were processed using zUMI 2.0 with STAR to generate expression profiles of both 5'-end containing UMIs and full-length non-UMI data. To extract UMIs, unique reads in zUMI find_pattern:ATTGCGCAATG (SEQ ID NO:26) were specified in file 1, and base_definition:cDNA(23-75) and UMI(12-19) were specified in the YAML file. UMIs were counted using a Hamming distance of 1 to collapse UMIs. To obtain full-length profiles in zUMI, base_definiton in the YAML file was set to cDNA(1-75) in file 1. Experiments involving HEK293FT cells were aligned and mapped to the human genome (hg38) using gene annotations from ENSEMBL GRCh38.91.

[0147] Reagents and conditions tested for Smartseq3 Dissolution conditions Concentration TX-100 0.1%, 0.15%, 0.2% Guanidine-HCl 100mM, 250mM, 300mM, 350mM , 400mM, 450mM, 500mM, 750m M, 1M, 1.25M, 1.5M, 2M Bovine serum albumin (BSA) 0.01mg / ml, 0.025mg / ml, 0. 05mg / ml, 0.1mg / ml, 0.25mg / ml, 0.5mg / ml, 1.0mg / ml, 2 .0mg / ml RNAse inhibitor 0.5U / μL, 1.0U / μL, 1.3U / μL PEG8000K(Lysis 2%, 2.5%, 4%, 5%, 6%, 7.5%, 9 + Percentage by RTvol) %, 10% Oligo dT (Table 1) 0.1 μM, 0.2 μM, 0.25 μM, 0.4 μM M, 0.5μM, 0.75μM, 1μM, 1.25 μM, 2 μM, 4 μM Proteinase K 0.01-1.25μg / μL dNTP(mM / each) 0.05mM, 0.1mM, 0.25mM, 0.3 mM, 0.4mM, 0.5mM, 0.75mM, 0 .8mM, 1mM, 1.25mM, 1.5mM, 1 .75mM, 2mM

[0148] Melting temperature 30 min at 37 °C 72°C for 1 min 72°C for 3 min 72°C for 10 min 72°C for 20 min 50℃ for 10 minutes, 80℃ for 10 minutes

[0149] RT buffer concentration Tris-HCl pH 7.0 50mM Tris-HCl pH 7.5 50mM Tris-HCl pH 8.0 20mM, 25mM, 30mM, 35mM, 40mM mM, 50 mM, 65 mM, Tris-HCl pH 8.3 20mM, 25mM, 30mM, 35mM, 40mM mM, 50 mM, 65 mM, Tris-acetate pH 7.5 50mM TAPS-NaOH pH8.4 50mM TAPS-KOH pH8.4 50mM

[0150] Alkaline Chloride and Salt Concentration KCl 75mM NaCl 25mM, 50mM, 75mM, 100mM, 125mM , 150mM CsCl 75 mM LiCl 75mM Ammonium sulfate 10mM, 20mM, 30mM

[0151] Mg / Mn source concentration MgCl22mM, 2.5mM, 3mM, 3.5mM, 4mM, 4.5mM, 5m M, 6mM, 9mM, 10mM, 12mM MgOAc 2mM, 2.5mM, 3mM, 3.5mM, 4mM, 4.5mM, 5 mM, 6 mM, 9 mM MgSO22mM, 2.5mM, 3mM, 3.5mM, 4mM, 4.5mM, 5m M, 6mM, 9mM MnCl20.1mM, 0.25mM, 0.5mM, 0.75mM, 1mM, 2m M, 3mM, 6mM

[0152] RT dNTP / NTP additive concentration GTP 0-4mM dGTP 0~4mM GMP 0~4mM dGMP 0~4mM dCTP 0~4mM CTP 0~4mM CMP 0-4mM dCMP 0-4mM

[0153] RT / PCR enhancer concentration Betaine 0.35M, 0.5M, 1M, 1.2M, 1.3M , 1.5M, 2M Bovine serum albumin (BSA) 0.01mg / ml, 0.025mg / ml, 0. 05mg / ml, 0.1mg / ml, 0.25mg / ml, 0.5mg / ml Glycerol 2%, 5%, 7%, 10% PEG300 1~10% PEG400 1~10% PEG8000 1~10% Glycogen 5% 1,2 Propanediol 5% DMSO 1~5% DMF 1-10% Tween-20 0.01-0.5% T4 gene 32 protein 0.01-1μg / μL Dithiothreitol (DTT) 5mM, 7.5mM, 10mM, 12.5mM, 1 5mM

[0154] Reverse transcriptase concentration Superscript II 2~10U / μL SuperscriptIII 10U / μL SuperscriptIV 10U / μL RevertAid H-minus 2~10U / μL Protoscript II 10U / μL Maxima H-minus 2~10U / μL EpiScript 10U / μL

[0155] RNAse inhibitor concentration Recombinant RNAse Inhibitor (RRI) 0.5U / μL, 1U / μL RNAseOUT 0.5U / μL, 1U / L

[0156] TSO (Table 2) Concentration 0.5μM, 0.75μM, 1μM, 1.5μM, 2μM, 4μM , 8μM, 12μM, 16μM

[0157] RT temperature 42°C for 90 min, 10x (50°C for 2 min, 42°C for 2 min), 70°C for 15 min 50°C for 90 min, 10x (50°C for 2 min, 42°C for 2 min), 85°C for 5 min 48°C for 90 min, 10x (50°C for 2 min, 42°C for 2 min), 85°C for 5 min 45°C for 90 min, 10x (50°C for 2 min, 42°C for 2 min), 85°C for 5 min 42°C for 90 min, 10x (50°C for 2 min, 42°C for 2 min), 85°C for 5 min 42°C for 90 min, 10x (50°C for 2 min, 42°C for 2 min) 42°C for 60 min, 10x (50°C for 2 min, 42°C for 2 min), 85°C for 5 min 42°C for 45 min, 10x (50°C for 2 min, 42°C for 2 min), 85°C for 5 min 42°C for 30 min, 10x (50°C for 2 min, 42°C for 2 min), 85°C for 5 min 42°C for 15 min, 10x (50°C for 2 min, 42°C for 2 min), 85°C for 5 min 50°C for 30 min, 10x (35°C for 2 min, 55°C for 2 min), 85°C for 5 min 10x (50°C for 2 min, 42°C for 2 min), 85°C for 5 min 10x (50°C for 3 min, 42°C for 2 min), 85°C for 5 min 10x (50°C for 2 min, 42°C for 4 min), 85°C for 5 min 10x (42°C for 3 min, 55°C for 2 min, 37°C for 1 min), 85°C for 5 min 90 min at 25°C, 10x (2 min at 50°C, 2 min at 25°C), 5 min at 85°C 42°C for 90 minutes, 85°C for 5 minutes 45℃ for 90 minutes, 85℃ for 5 minutes 48°C for 90 minutes, 85°C for 5 minutes 50℃ for 60 minutes, 85℃ for 5 minutes 50℃ for 90 minutes, 85℃ for 5 minutes 53°C for 90 minutes, 85°C for 5 minutes 55℃ for 90 minutes, 85℃ for 5 minutes 10x (10 min at 42°C, 2 min at 15°C), 10x (2 min at 50°C, 2 min at 42°C), 5 min at 85°C 10x (42°C for 7 min, 15°C for 2 min), 10x (50°C for 2 min, 42°C for 2 min), 85°C for 5 min 10x (55°C for 7 min, 15°C for 2 min), 10x (50°C for 2 min, 42°C for 2 min), 85°C for 5 min 10x (50°C for 3 min, 65°C for 3 min, 45°C for 3 min, 42°C for 3 min), 85°C for 5 min 10x (50°C for 3 min, 45°C for 3 min, 42°C for 3 min, 37°C for 3 min), 85°C for 5 min 10x (42°C for 10 min, 37°C for 2 min), 10x (50°C for 2 min, 42°C for 2 min), 85°C for 5 min 50°C for 10 min, 3x (8°C for 15 sec, 15°C for 45 sec, 20°C for 45 sec, 30°C for 30 sec, 42°C for 2 min, 50°C for 3 min), 50°C for 5 min, 85°C for 5 min

[0158] RT-PCR temperature 42°C for 90 min, 10x (50°C for 2 min, 42°C for 2 min), 98°C for 3 min, 20x (98°C for 20 sec, 63°C for 30 sec, 72°C for 6 min), 72°C for 5 min 45°C for 90 min, 10x (50°C for 2 min, 42°C for 2 min), 98°C for 3 min, 20x (98°C for 20 sec, 63°C for 30 sec, 72°C for 6 min), 72°C for 5 min 42°C for 90 min, 10x (50°C for 2 min, 42°C for 2 min), 98°C for 3 min, 20x (98°C for 20 sec, 65°C for 30 sec, 72°C for 6 min), 72°C for 5 min 45°C for 90 min, 10x (50°C for 2 min, 42°C for 2 min), 98°C for 3 min, 20x (98°C for 20 sec, 65°C for 30 sec, 72°C for 6 min), 72°C for 5 min 42°C for 90 min, 10x (50°C for 2 min, 42°C for 2 min), 98°C for 3 min, 20x (98°C for 20 sec, 67°C for 30 sec, 72°C for 6 min), 72°C for 5 min 45°C for 90 min, 10x (50°C for 2 min, 42°C for 2 min), 98°C for 3 min, 20x (98°C for 20 sec, 67°C for 30 sec, 72°C for 6 min), 72°C for 5 min

[0159] PCR kit and polymerase concentration KAPA HiFi HotStart PCR Kit Terra PCR Direct Polymerase Kit KAPA HiFi PCR Kit Q5 High Fidelity DNA Polymerase Platinum SuperFi DNA Polymerase Phusion High Fidelity DNA Polymerase PCR primers (Table 3) 0.05 μM, 0.08 μM, 0.1 μM

[0160] PCR temperature 98°C for 3 min 20x (98°C for 20 sec, 65°C for 30 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 18× (98°C for 20 sec, 65°C for 30 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 60°C for 30 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 61°C for 30 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 62°C for 30 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 63°C for 30 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 64°C for 30 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 65°C for 30 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 66°C for 30 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 67°C for 30 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 68°C for 30 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 69°C for 30 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 70°C for 30 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 71°C for 30 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 72°C for 30 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 60°C for 15 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 61°C for 15 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 62°C for 15 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 63°C for 15 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 64°C for 15 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 65°C for 15 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 66°C for 15 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 67°C for 15 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 68°C for 15 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 69°C for 15 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 70°C for 15 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 71°C for 15 sec, 72°C for 6 min), 72°C for 5 min 98°C for 3 min 20x (98°C for 20 sec, 72°C for 15 sec, 72°C for 6 min), 72°C for 5 min

[0161] [Table 1]

[0162] [Table 2-1]

[0163] [Table 2-2]

[0164]

Table 3

[0165]

Table 4-1

[0166]

Table 4-2

[0167]

Table 4-3

[0168]

Table 4-4

[0169]

Table 4-5

[0170]

Table 4-6

[0171]

Table 4-7

[0172]

Table 4-8

[0173]

Table 4-9

[0174]

Table 4-10

[0175]

Table 4-11

[0176]

Table 4-12

[0177]

Table 4-13

[0178]

Table 4-14

[0179]

Table 4-15

[0180]

Table 4-16

[0181]

Table 4-17

[0182] B.Result inspection To enable single-cell RNA sequencing with both full-length transcriptome information and UMI for RNA molecule quantification, a new single-cell RNA sequencing assay was designed starting from Smart-seq2. First, new oligonucleotides for reverse transcription, template switching, and preamplification were designed (Figure 1A-Figure 1B). For this purpose, we first experimented with template switching oligonucleotides (TSOs) modified to contain a partial Nextera P5 adapter sequence, a unique identification tag sequence, and a UMI consisting of Ns or Hs nucleotides as defined by the International Union of Pure and Applied Chemistry (IUPAC). Oligo-dT oligonucleotides were modified in terms of the length of the T stretch and terminal modifications. Preamplification PCR primers were modified to incorporate the remaining Nextera P5 adapter sequence at the 5' end of the captured cDNA. This enabled the sequencing of both 5'-terminal cDNA fragments carrying the unique identification tag and UMI, as well as fragments of the full-length transcript (Figure 7A-Figure 7B). The complete workflow is shown in Figure 1A-Figure 1B.

[0183] Based on this general design, a number of TSOs (Table 2), oligo-dT oligonucleotides (Table 1), and PCR oligonucleotides (Table 3) were experimentally tested. New oligonucleotide designs were evaluated based on their ability to capture RNA and amplify cDNA from HEK393T cells individually sorted into 96- or 384-well plates. cDNA products of oligonucleotide designs that resulted in high amplified cDNA yields and lengths were tagged, prepared for sequencing, and used in subsequent experiments. A number of reaction conditions and additives were systematically investigated for their ability to increase RNA capture and conversion to cDNA. The ILLUMINA® NextSeq500 sequencing system was used to monitor transcriptome complexity captured per cell and quantified in terms of number of genes detected per cell and number of unique UMIs detected per cell (after filtering out UMI sequences due to sequencing errors and those within one Hamming distance of another UMI). Significantly improved sensitivity was obtained compared to existing single-cell RNA sequencing assays, including Smart-seq2. Several reverse transcriptases have improved processivity and thermostability over SuperscriptII. For example, the reverse transcriptase Maxima H minus was used in a new reaction buffer that improves both gene capture and sensitivity at a significantly reduced cost. In the reverse transcriptase reaction, the amount of dNTPs (0.1 mM / each to 0.8 mM / each) and the range of MgCl2 (2 to 4 mM) were reduced, improving overall yield and sensitivity in the context of Maxima H Minus. To systematically evaluate the performance, 65 different variations of this general reverse transcription and template switching reaction were tested in addition to experiments with different additives (see below). The number of genes detected per cell in 65 different conditions is shown in Figure 2. Significantly improved gene detection compared to Smart-seq2 was observed in many different conditions. The increased sensitivity resulted in the detection of more polyadenylated noncoding RNAs, especially long intergenic noncoding RNAs (lincRNAs) (Figure 3).

[0184] Furthermore, cDNA conversion from RNA was improved by the addition of enhancement additives, specifically dCTP and GTP in the range of 0.1-2 mM, both alone and in combination, and the molecular crowding agent PEG in the range of 2-9%. Further addition of dCTP could increase the rate of C incorporation in the C-tail created by reverse transcriptase at the 3' end of the synthesized cDNA strand. Furthermore, the addition of complementary ribonucleotides to the template switching reaction has been shown to promote a longer or more stable non-templated C-tail when it reaches the 5' end of the RNA template in the context of Moloney murine leukemia virus reverse transcriptase (MMLV-RT). It was hypothesized that administration of complementary ribonucleotides (GTP) could be used to increase the efficiency of the template switching reaction for single-cell RNA sequencing. As shown herein, the addition of dCTP and GTP affected the genes captured in the resulting single-cell RNA sequencing library. The crowding agent PEG is believed to increase the enzyme reaction rate and efficiency by reducing the effective reaction volume. The crowding agent PEG significantly improved sensitivity both as a single additive or as GTP together with other additives (Figure 2).

[0185] To reduce the total hands-on time required for the construction of single-cell RNA sequencing libraries and to facilitate their high-throughput incorporation, we also demonstrated the possibility of performing reverse transcription and PCR pre-amplification in a one-step reaction instead of as a two-step reaction (Figure 2).

[0186] For various biological applications, it may be desirable to have a higher or lower fraction of UMI-containing 5' reads in the final sequencing library. For example, experiments that exploit genomic variation in the transcriptome will require a higher number of internal reads, whereas experiments that count RNA will require a higher coverage across the 5' end of the RNA. By modulating or tuning the tagging efficiency, the percentage of UMI-containing 5' reads in the sequencing library could be experimentally controlled. This modulation or tuning could be performed by changing the ratio of Tn5 to cDNA and / or by shortening the reaction time, thereby increasing or decreasing the percentage of UMI-containing 5' reads in the sequencing library (Figure 4). Overall, the length distribution of the sequencing library was a strong indicator of the fraction of UMI-containing 5' reads in the sequencing library (Figure 5), as longer fragments were more likely to contain 5' ends. The unique ability to capture UMIs at both the 5' end and internal RNA fragments, combined with experimental strategies to control their relative abundance in sequencing libraries, is a key advantage of the present invention.

[0187] RNA secondary structures have important functions and also affect the ability to reverse transcribe RNA into cDNA. In single-cell RNA sequencing applications, the use of NaCl or CsCl instead of KCl led to improved sensitivity of single-cell RNA sequencing reactions (Figure 6). KCl promotes four-stranded structures in RNA molecules that contain rG nucleotides, either intramolecularly or intermolecularly, and the observed improvement is likely due to a reduction in structured RNA that was more efficiently reverse transcribed into cDNA and thus captured in the sequencing of the resulting libraries. Note that the use of LiCl was worse than the use of standard KCl (data not shown).

[0188] FIG. 2 shows box plots showing the number of genes detected per cell for each of the 65 different test experimental conditions listed in Table 4. Condition 65 is the existing Smart-seq2 library. A wide variety of new reaction conditions using the present invention detect a significantly higher number of genes per cell compared to Smart-seq2. The number of unique cells analyzed per condition is displayed to the right of the box plot. The box plot has a default layout, i.e., the hinges indicate the first and third quartiles and the whiskers indicate 1.5× the interquartile range (IQR).

[0189] Figures 3A and 3B show box plots showing the number of genes detected per cell for a representative subset of experimental conditions tested (see Table 4) and classified by gene biotype. Note that in addition to significantly increasing detection of protein-coding RNA, the present invention also detects significantly more non-coding RNA, including lincRNA, compared to Smart-seq2. snoRNA in Figures 3A and 3B indicates small nucleolar RNA.

[0190] Figure 4 shows box plots depicting the percentage of 5'-end reads with UMIs in the sequencing libraries for condition 11 (see Table 4) of various tagging reaction conditions. Reducing the amount of Tn5 transposase present in the reaction reduced the efficiency of tagging, thereby leading to an increase in 5'-end containing reads with UMIs. Furthermore, reducing the amount of input cDNA or increasing the tagging reaction time resulted in higher tagging efficiency and fewer UMI-containing reads in the sequencing libraries. The starting cDNA was identical for all conditions shown in Figure 4, except for the conditions of various cDNA inputs.

[0191] Therefore, the ratio of 5' reads with UMIs to internal reads can be controlled or adjusted by controlling or adjusting the tagging efficiency, such as by controlling the amount of Tn5 transposase, controlling the amount of input cDNA, and / or controlling the tagging reaction time.

[0192] Figures 5A-C show the cDNA length distribution of differentially tagged cDNAs. The figures show Agilent BioAnalyzer traces of the libraries shown in Figure 4. The results shown in the figures verify that controlling the fragment length of the sequencing library allows control of the level of UMIs in the sequencing library.

[0193] Figures 6A through 6C show that gene detection can be increased by modifying reaction salts and experimental additives. Figure 6A shows a box plot showing the number of unique UMIs detected per cell, Figure 6B shows a box plot showing the number of genes detected by UMI-containing reads per cell, and Figure 6C shows a box plot showing the number of genes detected by all reads per cell. Three different salts were tested, NaCl, CsCl, and KCl, as indicated below the box plots. Additives 5% PEG, dCTP, and GTP were added to the reactions, as indicated below the box plots.

[0194] 7A and 7B show the read coverage across the RNA molecule for internal reads and UMI-containing 5'-end reads, respectively. As shown in the figures, the internal reads cover the RNA molecule, while the UMI-containing 5'-end reads are heavily biased toward the 5' end of the RNA molecule.

[0195] B. Example 1 and Specifications Reference [1] Islam et al., Characterization of single-cell transcriptional landscapes by highly multiplexed RNA-seq, Genome Research (2011) 21:1160-1167 [2] Hashimshony et al., CEL-Seq: Single-cell RNA-Seq by multiplexed linear amplification, Cell Reports (2012), 2(3):666-673 [3] Jaitin et al., Massively parallel single-cell RNA-Seq for marker-free disaggregation of tissues into cell types, Science (2014) 343(6172):776-779 [4] https: / / www.10xgenomics.com / single-cell-technology / [5] Rosenberg et al., Single-cell profiling of the developing mouse brain and spinal cord by split-pool barcoding, Science(2018), 360(6385):176-182 [6] Cao et al., Comprehensive single-cell transcriptional profiling of multicellular organisms, Science(2017), 357(6352):661-667 [7] Ramskold et al., Single-cell level RNA and full-length mRNA-Seq from individual circulating tumor cells, Nature Biotechnology (2012), 30:777-782 [8] WO2015 / 02713 [9] Tech Spotlight: ILLUMINA® Sequencing https: / / www.illumina.com / documents / products / techspotlights / techspotlight_sequencing.pdf (Retrieved December 20, 2018)

[10] Picelli et al., Smart-seq2 for sensitive full-length transcriptome profiling in single cells, Nature Methods(2013), 10(11):1096-1098

[11] Picelli, Full-length RNA-seq from single cells using Smart-seq2, Nature Protocols (2014), 9(1):171-181

[0196] II. Example 2 - Single-cell RNA counting with allele and isoform resolution using Smart-seq3 A. Introduction Large-scale sequencing of RNA from individual cells can reveal patterns of gene, isoform and allele expression across cell types and states 1However, current single-cell RNA sequencing (scRNA-seq) methods are limited in their ability to count RNA with allele and isoform resolution, and long-read sequencing technologies lack the depth required for large-scale applications across cells. 2,3 Here, we introduced Smart-seq3, which combines full-length transcriptome coverage with a 5' unique molecular identifier (UMI) RNA counting strategy, allowing in silico reconstruction of thousands of RNA molecules per cell. Importantly, the majority of counted and reconstructed RNA molecules could be directly assigned to specific isoform and allelic origins, and we observed significant transcript isoform regulation in mouse lineages and human cell types. Furthermore, Smart-seq3 showed a dramatic increase in sensitivity, typically detecting thousands more genes per cell than Smart-seq2. Overall, we developed a short-read sequencing strategy for single-cell RNA counting at isoform and allele resolution that can be applied to large-scale characterization of cell types and states across tissues and organisms.

[0197] Most scRNA-seq methods count RNAs by sequencing UMIs along with a short portion of the RNA (from either the 5' or 3' end) 4 Although these RNA end-counting strategies have been effective for estimating gene expression across large numbers of cells while controlling for PCR amplification bias, RNA end-sequencing provides little information about transcript isoform expression or transcribed genetic variation. Furthermore, many massively parallel methods suffer from fairly low sensitivity (i.e., they capture only a small fraction of the RNA present in a cell). 5 In contrast, Smart-seq2 combines higher sensitivity with full-length coverage. 6 , which has enabled allele-resolved expression analysis, for example. 7However, they have been slow to implement, have been costly, and have not incorporated UMIs. Sequencing of full-length transcripts using long-read sequencing technologies can directly quantify allele- and isoform-level expression, but their current depth precludes their broad application across cells, tissues, and organisms. 2,3 To overcome these shortcomings, we sought to expand the RNA counting paradigm to develop a highly sensitive short-read sequencing method that directly assigns individual RNA molecules to their isoform and allelic origin in single cells.

[0198] B. Materials and Methods cell culture HEK293FT cells (Invitrogen) were cultured in complete DMEM medium containing 4.5 g / L glucose and 6 mM L-glutamine (Gibco) and supplemented with 10% fetal bovine serum (Sigma-Aldrich), 0.1 mM MEM non-essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco) and 100 μg / mL penicillin / streptomycin (Gibco). Cells were detached using TrypLE express (Gibco) and stained with propidium iodide to exclude dead cells, then dispensed into 96- or 384-well plates containing 3 μL of lysis buffer using a BD FACSMelody 100 μm nozzle (BD Bioscience). Smart-seq3 lysis buffer contains 0.5 units / μL recombinant RNase inhibitor (RRI) (Takara), 0.15% Triton X-100 (Sigma), 0.5 mM dNTPs / each (Thermo Scientific), 1 μM Smart-seq3 oligo dT primer (5'-biotin-ACGAGCATCAGCAGCATACGA T 30 VN-3' (SEQ ID NO:77; IDT), 5% PEG (Sigma) and 0.05 μL of 1:40.000 diluted ERCC spike-in mix 1 (for HEK293FT cells). Immediately after sorting, plates were spun down and stored at -80°C.

[0199] Primary mouse fibroblasts were obtained from tail explants of adult mice from CAST / EiJ × C57 / Bl6J (with ethical approval from the Swedish Board of Agriculture, Jordbruksverket: N343 / 12). Cells were cultured and passaged twice in (DMEM high glucose (Invitrogen), 10% ES cell FBS (Gibco), 1% penicillin / streptomycin (Invitrogen), 1% non-essential amino acids (Invitrogen), 1% sodium pyruvate (Invitrogen), 0.1 mM b-mercaptoethanol (Sigma)) and then stained with propidium iodide and sorted in 384-well plates containing 3 μL of Smart-seq3 lysis buffer. Plates were spun down again and stored at -80 °C immediately after sorting.

[0200] Human Cell Atlas (HCA) reference samples consisting of human PBMCs, mouse colon, and a mix of fluorescently labeled cell lines HEK-293-RFP, NiH3T3-GFP, and MDCK-Turbo650 were thawed according to the instructions provided. 4 Cells were stained with the Live / Dead Fixable GreenDead Cell Stain Kit (Invitrogen), which facilitated the exclusion of dead cells as well as NIH3T3-GFP cells. Additionally, both debris and doublets were excluded by gating. Cells were index-sorted into 384-well plates containing 3 μL of Smart-seq3 lysis buffer using a BD FACSMelody sorter (BD Bioscience) with a 100 μm nozzle.

[0201] Generation of Smart-seq2 libraries Smart-seq2 cDNA libraries were generated according to published protocols. 22 For Smart-seq2-UMI, cDNA libraries were generated as previously published 12 Recipes for other "intermediate" Smart-seq2 reactions are found in Table 4. Tagging was performed with similar cDNA inputs and volumes as Smart-seq3, described below.

[0202] Generation of Smart-seq3 libraries To facilitate cell lysis and RNA denaturation, plates were incubated at 72°C for 10 min and then immediately placed on ice. Next, 1 μL of reverse transcription mix containing 25 mM Tris-HCL pH 8.3 (Sigma), 30 mM NaCl (Ambion), 1 mM GTP (Thermo Scientific), 2.5 mM MgCl2 (Ambion), 8 mM DTT (Thermo Scientific), 0.5 u / μL RRI (Takara), 2 μM of different Smart-seq3 template switching oligos (TSOs) (see supplementary table for list of TSOs evaluated; 5'-biotin-AGAGACAGATTGCGCAATGNNNNNNNNNrGrGrG-3' (SEQ ID NO:78); IDT) and 2 u / μL Maxima H Minus reverse transcriptase (Thermo Scientific) was added to each sample. Reverse transcription and template switching were performed at 42°C for 90 min, followed by 10 cycles of 50°C for 2 min and 42°C for 2 min. The reaction was stopped by incubating at 85°C for 5 min. PCR preamplification was performed directly after reverse transcription by adding 6 μL of PCR mix and adjusting the reaction concentrations to 1× KAPA HiFi PCR buffer (with 2 mM MgCl2 at 1×) (Roche), 0.02 u / μl DNA polymerase (Roche), 0.3 mM dNTPs, 0.1 μM Smartseq3 forward PCR primer (5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGATTGCGCAATG-3′ (SEQ ID NO:79); IDT), 0.1 μM Smartseq3 reverse PCR primer (5′-ACGAGCATCAGCAGCATACGA-3′ (SEQ ID NO:80); IDT). PCR was cycled as follows: The protocol consisted of 3 min at 98 °C for initial denaturation, followed by 20-24 cycles of 20 s at 98 °C, 30 s at 65 °C, and 6 min at 72 °C. Final extension was at 72 °C for 5 min. For various iterations and optimization conditions, see Supplementary Table 1 for information on specific conditional modifications to library preparation.

[0203] Sequencing library preparationAfter PCR preamplification, all samples, regardless of the protocol used, were purified with AMpure XP beads (Beckman Coulter) or homemade 22% PEG beads (see step 27 of protocoldoi:10.17504 / protocols.io.p9kdr4w at protocols.io). Library size distribution was checked with a high-sensitivity DNA chip (Agilent Bioanalyzer) and all cDNA concentrations were quantified using the Quant-iT PicoGreen dsDNA Assay Kit (Thermo Scientific). cDNA was subsequently diluted to 100-200 pg / uL. Tagging was performed in 2 uL of 1x tagging buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 5% DMF), 0.08-0.1 uL ATM (Illumina XT DNA Sample Preparation Kit) or TDE1 (Illumina DNA Sample Preparation Kit), 1 uL cDNA and HO. Plates were incubated at 55°C for 10 min, followed by the addition of 0.5uL of 0.2% SDS to release Tn5 from the DNA. Library amplification of tagged samples was performed using either 1.5uL of Nextera XT index primers (Illumina) or 1.5uL of custom-designed Nextera index primers containing 8 or 10bp indexes (0.1uM each), differing with a minimum Levenshtein distance of 2 between any two indexes. 3uL PCR mix (1x Phusion Buffer (Thermo Scientific), 0.01U / uL Phusion DNA Polymerase (Thermo Scientific), 0.2mM dNTPs / each) was added to each well and incubated in a thermal cycler for 3 min, 72°C; 12 cycles of (10 sec, 95°C; 30 sec, 55°C; 30 sec, 72°C); 5 min, 72°C). Subsequent modifications to the tagmentation procedure (cDNA input, amount of ATM, time at 55°C) are shown in Figure 9c for experiments optimizing UMI fragment conditions. After tagmentation, samples were pooled and the pool was purified with Ampure XP beads or 22% homemade PEG beads at a 1:0.6 ratio.Libraries were sequenced 75bp single-end or 150bp paired-end on a high-output flow cell using an Illumina NextSeq500 instrument, or 150bp paired-end on a NovaSeq S4 flow cell.

[0204] Gel cutting pilot Additionally, we performed an experiment by selecting libraries of specific lengths before sequencing mouse fibroblasts. We used 20uL of purified sequence-ready library, loaded it onto 2% agarose E-Gel EX, and ran the gel for 12 minutes. We manually cut the gel at the region corresponding to 550-2000bp and repurified the library using Qiagen QiaQuick Gel Extraction Kit according to the manufacturer's protocol. Modest improvement was observed, but selecting longer fragments may improve the length of the reconstruction.

[0205] Read alignment and gene expression estimation Raw non-demultiplexed fastq files were processed in STAR (v2.5.4b) using zUMI (version 2.4.1 or later) to generate expression profiles for both the 5' end containing UMI and the combined full-length and UMI data. To extract and identify UMI-containing reads in zUMI, we specified find_pattern:ATTGCGCAATG (SEQ ID NO:81) for file 1 and base_definition:cDNA(23-75; single-end), (23-150bp, paired-end) and UMI(12-19) in the YAML file. UMIs were collapsed using a Hamming distance of 1. Human cells were mapped to the hg38 genome and mouse fibroblasts were mapped against the mm10 genome, CAST SNPs were masked with N to avoid mapping bias, and both had the additional STAR parameters "--limitSjdbInsertNsj 2000000 --outFilterIntronMotifs --RemoveNoncanonicalUnannotated --clip3pAdapterSeq CTGTCTCTTATACACATCT" (SEQ ID NO:82) added. Experiments involving HEK293FT cells were quantified using gene annotations from Ensembl GRCh38.91. Mouse primary fibroblast data were quantified using gene annotations from Ensembl GRCm38.91.

[0206] Allele calling of F1 mouse molecules CAST / EiJ lineage-specific SNPs were identified in the Mouse Genome Project 23 Retrieved from dbSNP142 and filtered for variants clearly observed in existing CAST / EiJ × C57 / Bl6J F1 data, 1,882,860 high-quality SNP positions were obtained. Uniquely mapped read pairs were extracted and analyzed for CIGAR values ​​using the GenomicAlignments package. 24Reads covering known high-quality SNPs were retained and grouped by UMI sequence. Molecules with >33% of bases at SNP positions that did not represent either the CAST or C57 allele were discarded, and >66% of SNP bases had to be observed in a molecule to represent one of the two alleles for an assignment to be made.

[0207] Inference of transcriptional burst dynamics Allele-resolved UMI counts were used to generate maximum likelihood estimates of burst kinetics from scRNA-seq data as previously described 12 Inference scripts are available at https: / / github.com / sandberg-lab / txburst. To ensure a fair comparison with the data generated in this study, we reprocessed the Smart-seq2 data deposited in the European Nucleotide Archive accession E-MTAB-7098 using zUMIs and the same set of SNPs as above.

[0208] Primary data processing of mixed-species benchmark samples The complete dataset was mapped against the combined reference genomes for human (hg38), mouse (mm10), and dog (CanFam3.1). Cells mapping unambiguously (>75% reads) to mouse or dog were removed. The remaining cells, representing HEK293, PBMC, and potential low-quality libraries, were processed using zUMI (version 2.5.5) and mapped only against the human genome.

[0209] Analysis of human HCA benchmark samples Cells were first filtered for low-quality libraries requiring >10,000 raw reads, >75% of reads mapped to the genome, and >25% exonic fraction. Cells with >500 genes detected were then filtered for low-quality libraries requiring >10,000 raw reads, >75% of reads mapped to the genome, and >25% exonic fraction. 25Further analysis was performed within v3.1 of the protocol (quantification of introns + exons). Data were normalized ('LogNormalize'), scaled to 10,000 and regressed on the total number of counts per cell. The top 2,000 distinct genes were found using the 'vst' method and used for PCA dimensionality reduction. The first 20 principal components were used for both SNN neighborhood construction as well as UMAP dimensionality reduction. Finally, Louvain clustering was applied (resolution = 0.7) to find cell groupings. Major cell types were easily distinguished by common marker genes: CD4+ T cells (CD4, IL7R, CD3D, CD3E, CD3G), CD8+ T cells (CD8A, CD8B), CD14+ monocytes (CD4, CD14, S100A12), FCGR3A+ monocytes (FCGR3A), B cells (MS4A1, CD19, CD79A), NK cells (NKG7, LYZ, NCAM1) and HEK cells (numerous genes detected). Naive T cells were separated from activated by the absence of CCR7, SELL, CD27, IL7R and FAS, TIGIT, CD69. γδ T cells were separated from other T cells by the absence of TRGC1, TRGC2, TRDC and TRAC, TRBC1, TRBC2.

[0210] Isoform reconstruction of UMI-linked fragments from Smart-seq3 Genomic alignments of 5'UMI-containing reads with their paired reads from the same fragment were generated by zUMI (version 2.4.1 or later) with UMI and cell barcode error correction. Unique and multi-mapped reads from the same molecule that mapped to exonic regions were used for isoform reconstruction. Genomic locations of exons from each isoform were based on reference gene annotations from Ensembl GRCm38.91 for mouse fibroblast data and Ensembl GRCh38.95 for human HCA data. Reads mapping to the same molecule were compared to the annotated transcript structure and represented as Boolean strings indicating which exons were found at the read pair and junctions ("1") and at junctions supporting exon exclusion ("0"). For exons not covered by the reads, "N" was used to indicate absence. Boolean strings from the reconstructed molecule were matched against strings corresponding to each reference isoform of the same gene, and compatible isoform(s) for each molecule were returned. Molecular isoform assignments were further refined based on reads aligning to alternative 5′ and 3′ splice sites of overlapping exons from different isoforms.

[0211] Isoform assignment by integrating non-UMI reads Transcriptome bam files generated using zUMI were demultiplexed per cell, and isoform abundances were determined using the Salmon 15(v0.14.0) Quantified using the quant command with the following settings: "--fldMean 700 --fldSD 100 --fldMax 2000 --minAssignedFrags 1 --dumpEqWeights". Fixed Salmon output for cases where all reads were assigned to one of many possible isoforms belonging to the same equivalence class. For each cell, isoforms with TPM>0 from salmon were considered expressed and used to filter compatible isoforms for the reconstituted molecule. If multiple isoforms were compatible with the reconstituted molecule (after Salmon filtering), each compatible isoform got a partial molecule count (1 / N compatible isoforms).

[0212] Lineage-specific isoform expression in mouse fibroblasts To investigate mouse strain-specific isoform expression, we used all molecules with both the assigned allele and only the assigned unique isoform. Only genes for which we detected two or more isoforms and expression from both alleles were considered. For each gene, a contingency table was created based on the counts of molecules assigned to each allele and isoform. Significance was tested using a chi-square test, and the resulting p-values ​​were corrected for multiple testing using the Benjamini-Hochberg procedure. Furthermore, we probed for significant strain-isoform interactions (with adjusted p-values ​​<0.05). For each significant gene, we performed one thousand independent randomizations of allele and isoform labels for all molecules and calculated the chi-square test for each permutation, further requiring that the actual p-value obtained was less than the 5% lowest p-value from the randomization.

[0213] C. Results Smart-seq2 6We systematically evaluated reverse transcriptases and reaction conditions that could improve the sensitivity, i.e., the number of RNA molecules detected per cell, compared to previous studies. Our efforts focused on improving a Smart-seq2-like assay that preserves full-length transcript coverage, and therefore consists of oligo-dT priming, reverse transcription followed by template switching, full cDNA amplification using PCR, and finally Tn5-based tagging and library construction (Figure 9a). After evaluating hundreds of different reaction conditions in HEK293T cells, we sequenced the most noteworthy conditions (Figure 10 and Table 4), and compared them with those in recent studies. 8 In line with this, the highest sensitivity was obtained using Maxima H-Minus reverse transcriptase (hereafter referred to as Maxima). It should be noted that switching the salt from KCl to NaCl or CsCl during reverse transcription improved the sensitivity of the Maxima-based single-cell reaction compared to standard KCl conditions (Figure 11), likely due to reduced RNA secondary structure. 9 Furthermore, performing reverse transcription in 5% PEG has been shown to 8 , improving yield and stabilizing or facilitating the template switching reaction. 10 or dCTP was added (Figure 11). Although many DNA polymerase enzymes were tested, KAPA HiFi Hot-Start polymerase remained the most compatible with the reaction chemistry and yielded the highest sensitivity. Importantly, the partial Tn5 motif 11We constructed a template-switching oligo (TSO) containing a novel 11bp tag sequence followed by an 8bp UMI sequence and a primer site consisting of three riboguanosines, the latter of which hybridizes to non-templated nucleotides overhanging the end of single-stranded cDNA. After sequencing, the 11bp tag can be used to clearly distinguish between 5'UMI-containing reads and internal reads (Figure 9a). Thus, in the same sequencing reaction, we obtain strand-specific 5'UMI-containing reads and non-stranded internal reads spanning the full transcript without UMIs (Figure 9b). The ratio of 5' to internal reads could be adjusted by modifying the Tn5-based tagging reaction (Figure 9c). We named the final protocol Smart-seq3, which significantly improved the detection of polyA+ protein-coding (Figure 9d) and non-coding RNA (Figure 12) in HEK293FT cells. Compared to Smart-seq2, cell-to-cell correlation of gene expression profiles was significantly improved with Smart-seq3 (Figure 9e), revealing remarkable complexity in the HEK293T cell transcriptome, where up to 150,000 unique molecules were detected (Figure 9f). Remarkably, when comparing Smart-seq3 with single-molecule RNA-FISH, Smart-seq3 detected up to 80% of the molecules detected by smRNA-FISH per cell. 12 , revealing that it detected an average of 69% of smRNA-FISH molecules across the four genes tested (Fig. 9g, h). Overall, this indicates that Smart-seq3 significantly improves sensitivity compared to Smart-seq2, even approaching the sensitivity of smRNA-FISH.

[0214] We next developed a strategy for in silico reconstruction of RNA molecules. Importantly, because PCR preamplification of full-length cDNA in Smart-seq3 is followed by Tn5 tagging, copies of the same cDNA molecule with the same UMI acquire variable 3' ends that map to different parts of a given transcript (Fig. 13a). Thus, paired-end sequencing of these libraries yields 3'-end sequences spanning different parts of the initial cDNA molecule that can be computationally linked to specific molecules based on their 5'UMI sequences, thus enabling parallel reconstruction of RNA molecules (Fig. 13a). To experimentally investigate the reconstruction of RNA molecules, we generated Smart-seq3 libraries from 369 individual primary mouse fibroblasts (F1 progeny of CAST / EiJ and C57 / Bl6J strains) and performed paired-end sequencing. Aligned and UMI error-corrected read pairs 13 were surveyed and linked to molecules by their UMI and alignment start coordinates. An example of read pairs originating from a specific molecule transcribed from the Cox7a2l locus in a single fibroblast is shown in Figure 14. We then investigated the frequency with which the reconstructed portion of the RNA molecule covered lineage-specific single nucleotide polymorphisms (SNPs). Strikingly, unambiguous discrimination of allelic origin by direct sequencing of SNPs in UMI-linked reads was observed for 61% of all detected molecules (Figure 13b), with the assignment percentage increasing with increasing SNP density within the transcript (Figure 13c). Previous single-cell studies estimated allelic expression as the product of RNA quantification (in molecules or RPKM) and the fraction SNP-containing reads supporting each allele. 7,12,14We next investigated how these estimates compared to direct allelic RNA counts were possible with Smart-seq3. Encouragingly, estimates of allelic expression and direct allelic RNA counts showed an overall good correlation when aggregated across cells (Fig. S13d). Furthermore, using a linear model to quantify the agreement of the two measures across genes in cells revealed a strong correlation (Spearman rho = 0.82 ± 0.08 and slope = 0.88 ± 0.06) without any apparent bias (intercept = 0.06 ± 0.03) (Fig. S13e). Thus, direct allelic RNA counts are feasible in single cells, validating previous efforts to estimate allelic expression from isolated expression and allelic estimation in single cells. 7,12,14 .

[0215] We have previously shown that allele-resolved scRNA-seq can be used to infer burst dynamics of gene expression characteristic of transcription. 12 Remarkably, Smart-seq3-based analysis enabled dynamics inference for thousands more genes than using Smart-seq2 alone with 5'UMI (11,766 using Smart-seq3 and 8,464 using Smart-seq2-UMI) and significantly improved the correlation between CAST and C57 alleles (0.94 and 0.75 for Smart-seq3, and 0.79 and 0.68 for Smart-seq2-UMI for burst frequency and size, respectively) (Figure S13f and Figure S15). We conclude that Smart-seq3 enables more sensitive reconstruction of transcriptional burst dynamics across single cells.

[0216] We investigated the length of the reconstructed RNAs to what extent they contain information about the isoform structure of the transcripts. In experiments with 369 cells, we observed that a total of 22,196 molecules were reconstructed to lengths of 1.5 kb or more, and approximately 200,000 molecules were reconstructed to lengths of 1 kb or more (Figure 13g). Per cell, 8,710 molecules were reconstructed to lengths of 500 bp or more. Importantly, reconstructed molecules can often be assigned to specific transcript isoforms, as exemplified here by a sashimi plot of two reconstructed molecules from the Cox7a2l gene (Figure 13h), which shows how reconstructed sequences overlapping exons and splice junctions assign molecules to transcript isoforms. Interestingly, 53% of all reconstructed molecules could be assigned to a single annotated Ensembl isoform, including 41% of all molecules detected from multi-isoform genes (Figure 13i), thus allowing RNA counting at isoform resolution.

[0217] Conventional single-cell or population-level RNA sequencing does not allow for simultaneous quantification of lineage-specific SNPs and splicing outcomes on the same RNA, making it difficult to study the regulation of lineage-specific transcript isoforms. In silico assignment of reconstructed molecules to both allelic origin and transcript isoform structure revealed statistically significant lineage-specific (CAST or C57) expression of transcript isoforms for 2,172 genes (adjusted p-value < 0.05, chi-squared test with Benjamini-Hochberg correction; and p-value < 0.05, gene-specific permutation test) (Figure 13j). For example, the transcript for Hcfc1r1 was processed into two isoforms (ENSMUST00000024697 and ENSMUST00000179928) that differed both in the coding sequence (a 3 amino acid deletion from a 12-bp alternative 3' splice site usage) and in 5' untranslated region splicing. Surprisingly, the two isoforms showed significant mutually exclusive expression patterns between lineages (adjusted p-values ​​<10 -208, chi-squared test with Benjamini-Hochberg correction) (FIG. 13k). Thus, Smart-seq3 can simultaneously quantify genotype and splicing outcomes, as exemplified here by mouse strain-specific splicing patterns.

[0218] We next benchmarked Smart-seq3 on more complex samples consisting of many different cell types. To this end, we used the HCA benchmark sample 4 We sequenced 5,376 individual cells from a cryopreserved complex cellular sample consisting of human peripheral blood mononuclear cells (PBMCs), primary mouse colon cells, and cell lineage spike-ins of human HEK293T, mouse NIH3T3 and canine MDCK cells. Smart-seq3 cells were clearly separated according to species (Figure 16) and cell type (Figure 17a), with 77% of cells passing quality filtering, which is consistent with the available protocols. 4 This is a significantly higher percentage than the 29% to 63% reported for ( 18 ), demonstrating the robustness of Smart-seq3.

[0219] With the exception of CD14+ monocytes, which may be more vulnerable to a year of freezer storage prior to FACS cell sorting and Smart-seq3 profiling, gene detection sensitivity was significantly higher for all cell types compared to Smart-seq2, which are already at a shallower sequencing depth (Figure 17b). This improvement in the number of detected genes extended to previously challenging cell types with low mRNA content, such as T and B cells, where typically as many as 1000 more genes per cell were observed. Interestingly, we detected two distinct clusters of B cells (Figure 17a) that were not separated in the single-cell data from existing methods. 4 Differential expression between B cell populations revealed 279 genes with significant differential expression, including several known marker genes for naive and memory B cells (Figure 17c). This indicates an improved ability of Smart-seq3 to isolate biologically meaningful clusters of cells compared to existing methods.

[0220] Investigating RNA molecule reconstruction performance across human cell types revealed that 36–41% of all detected molecules could be assigned to specific isoforms across cell types (Figure 17d). To investigate isoform assignment in more detail, we visualized the number of compatible isoforms for each reconstructed RNA molecule and binned genes by the number of annotated isoforms. Many additional molecules could be assigned to a small set of transcript isoforms (Figure 17e). Furthermore, we reasoned that Smart-seq3 internal reads might provide more information about isoform expression. To this end, we analyzed the Salmon genomic DNA sequence of all reads from Smart-seq3. 15 We calculated isoform expression using and filtered the direct RNA reconstruction-based assignment of molecules to only those isoforms with detectable expression (TPM>0) in Salmon. This strategy further increased the assignment of molecules to unique isoforms (42% of all molecules) (Figure ​(Figure17f),17), and we used the Salmon-filtered isoform expression levels for the remainder of the study.

[0221] We next investigated patterns of isoform expression across cell types. Surprisingly, 2,186 genes had statistically significant patterns of isoform expression across cell types (adjusted p-value < 0.05; Kruskal-Wallis test and Benjamini-Hochberg correction). One key gene was PTPRC (also known as CD45), which is expressed in several different isoforms, including a full-length isoform (termed RABC) and one that excludes three consecutive exons (termed RO). 16It can be post-transcriptionally processed to the nucleoids. We predominantly observed these two isoforms across human immune cell types, albeit at widely differing levels (Fig. 17g). Aggregating reads supporting these two isoforms in gamma delta T cells (Fig. 17h) further shows how the reconstitution molecules separated the inclusion or skipping of three consecutive exons. Other specific isoform patterns were shared across specific cell types. For example, both CD14+ and FCGR3A+ monocytes expressed specific isoforms of the TIMP1 gene (Fig. 17i, j). Both monocyte populations specifically expressed the shorter isoform of the TIMP1 gene, while the long full-length isoform predominated across other cell types (Fig. 17i), again supported by the reconstitution molecules (Fig. 17j). Overall, these results highlight the new and unique capabilities of using Smart-seq3 to query isoform expression and regulation across cell types.

[0222] D. Discussion Mammalian genes typically generate multiple transcript isoforms from each gene. 17 , frequently affecting RNA and protein function. Analysis of transcript isoform expression (in single cells or in cell populations) using short-read sequencing technologies has often focused on individual splicing events (e.g., skipped exons) or used read coverage of shared and unique isoform regions to infer the most likely isoform expression. 18,19 This is due to paired short reads that rarely have enough information to assess interactions between distal splicing outcomes or combined with allelic expression from transcribed genetic variants. Using long-read sequencing technologies, transcript isoforms can be sequenced directly in single cells. 2,3 However, these strategies are limited in cellular throughput and depth. For example, the Mandalorion approach provided comprehensive isoform data for seven cells, but 2, scISOr-seq surveyed isoform expression in thousands of cells at an average depth of 260 molecules per cell 3 In contrast, an average of 8,710 reconstituted molecules (>500 bp) were obtained per cell. Furthermore, in scISOr-seq, pre-amplified cDNA was sequenced in parallel on both short-read and long-read sequencers to characterize cell types and subtypes, and isoform-level sequencing data were primarily aggregated across cells according to clusters. 3 Using two parallel library construction methods and sequencing technologies on the same pre-amplified cDNA from individual cells significantly increases costs and labor.

[0223] We developed Smart-seq3 to be highly sensitive, thus improving the ability to discriminate cell types and states, and isoform-specific, allowing the simultaneous reconstruction of millions of partial transcripts across cells. Thus, Smart-seq3 eliminates the additional costs and efforts associated with the parallel use of multiple library preparation techniques and sequencing platforms. Compared to known transcript isoform annotations, these partial transcript reconstructions were sufficient to assign 40-50% of the detected molecules to specific isoforms, further revealing lineage- and cell type-specific isoform regulation. Excitingly, this reconstruction should improve the ability to perform splicing quantitative trait locus mapping, since both splicing outcomes and transcribed SNPs can now be directly quantified. The complete Smart-seq3 protocol has been deposited at protocols.io (dx.doi.org / 10.17504 / protocols.io.7dnhi5e) and can be easily implemented in any molecular biology laboratory without the need for special equipment.

[0224] Several large-scale projects aim to systematically build cell atlases spanning human tissues and model organisms. 20These efforts increasingly rely on scRNA-seq methods that count RNA towards annotated gene ends (e.g., 10x Genomics), which provide little information about isoform expression patterns across cell types and tissues. In addition, large-scale efforts are also emerging that use single-cell genomics for the systematic analysis of disease (e.g., the LifeTime project) to identify disease mechanisms and outcomes. Because post-transcriptional gene regulation is closely linked to disease, 21 , a missed opportunity for such efforts and atlases would be to neglect isoform-level expression patterns. In contrast to long-read sequencing efforts, Smart-seq3 simultaneously offers cost-effective gene expression profiling across cell types and isoform-resolved RNA counting within the same assay. This is currently achieved at a cost per sequencing-ready cell library of approximately 0.5–1 EUR. Furthermore, because the current implementation uses 384-well plates, it is also possible to shallowly sequence all cells first and later select cells from rare cell populations for in-depth sequencing and transcript isoform reconstruction (as cell-amplified cDNA can be retained for long periods in individual wells). Overall, we have introduced an applicable scRNA-seq method to characterize cell types and annotate cell atlases at the level of gene, isoform and allele expression.

[0225] E. Reference to Example 2 1. Sandberg, R. Entering the era of single-cell transcriptomics in biology and medicine. Nat. Methods 11, 22-24(2014). 2. Byrne, A. Nanopore long-read RNAseq reveals widespread transcriptional variation among surface receptors on individual B cells. Nat. Commun. (2017). 3. Gupta, I. et al. Single-cell isoform RNA sequencing characterizes isoforms in thousands of cerebellar cells. Nat Biotechnol. (2018) doi:10.1038 / nbt.4259. 4. Mereu, E. et al. Benchmarking single-cell RNA sequencing protocols from the Cell Atlas Project. bioRxiv 630087(2019)doi:10.1101 / 630087. 5. Ziegenhain, C. et al. Comparative analysis of single-cell RNA sequencing methods. Mol. Cell 65, 631-643. e4 (2017). 6. Picelli, S. et al. Smart-seq2 for sensitive full-length transcriptome profiling in single cells. Nat. Methods 10, 1096-1098(2013). 7. Deng, Q., Ramskold, D., Reinius, B. & Sandberg, R. Single-cell RNA-seq reveals dynamic and random monoallelic gene expression in mammalian cells. Science 343, 193-196(2014). 8. Bagnoli, J. Wet al. Highly sensitive and powerful single-cell RNA sequencing with mcSCRB-seq. Nat. Commun. 9, 2937 (2018). 9. Guo, JU & Bartel, DP RNA G-quadruplexes are globally deployed in eukaryotic cells and deplete bacteria. Science 353, (2016). 10. Ohtsubo, Y., Nagata, Y. & Tsuda, M. Compounds that enhance the tailing activity of Moloney murine leukemia virus reverse transcriptase. Sci.Rep.7,6520(2017). 11. Cole, C., Byrne, A., Beaudin, A. E., Forsberg, E. C. & Vollmers, C. Tn5 Prime, a Tn5-based 5' capture method for single-cell RNA-seq. Nucleic Acids Res. 46, e62 (2018). 12. Larsson, A. J. Met al. Genomic encoding of transcriptional burst dynamics. Nature 565, 251-254 (2019). 13. Parekh, S., Ziegenhain, C., Vieth, B., Enard, W. & Hellmann, I. zUMI - A fast and flexible pipeline for processing RNA sequencing data using UMI. GigaScience 7, (2018). 14. Reinius, B. et al. Analysis of allelic expression patterns in clonal somatic cells by single-cell RNA-seq. Nat Genet. 48, 1430-1435 (2016). 15. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast, bias-aware quantification of transcript expression. Nat. Methods 14, 417-419(2017). 16. Martinez, NM & Lynch, KW. Control of alternative splicing in the immune response: many regulators, many predictions, and much still to be learned. Immunol. Rev. 253, 216-236(2013). 17. Wang,ET et al. Alternative isoform regulation in human tissue transcriptomes. Nature 456, 470-476(2008). 18. Katz, Y., Wang, E. T., Airoldi, E. M. & Burge, C. B. Analysis and design of RNA sequencing experiments to identify isoform regulation. Nat. Methods 7, 1009-1015 (2010). 19. Trapnell, C. et al. Differential analysis of gene regulation at transcript resolution using RNA-seq. Nat. Biotechnol. 31, 46-53 (2013). 20. Regev, A. et al. Human Cell Atlas. eLife 6, (2017). 21. Scotti, MM & Swanson, MS. RNA missplicing in disease. Nat. Rev. Genet. 17, 19-32 (2016). 22. Picelli, S. et al. Full-length RNA-seq from single cells using Smart-seq2. Nat. Protoc. 9, 171-181 (2014). 23. Keane,TMet al. Mouse genomic variation and its effects on phenotype and gene regulation. Nature 477,289-294(2011). 24. Lawrence, M. et al. Software for calculating and annotating genome coverage. PLoS Comput. Biol. 9, e1003118 (2013). 25. Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888-1902. e21 (2019).

[0226] Example 3: Use of the method to improve the analysis of metagenomic samples A metagenomic sample can contain nucleic acids from a wide collection of different microbial species, such as bacteria. A common method in the art for identifying species present in a sample is to perform amplicon-based NGS library sequencing of segments of rRNA genes. See, for example, https: / / genohub.com / shotgun-metagenomics-sequencing / . This method relies on the fact that rRNA genes are generally highly conserved between species, so primers for amplicon sequencing can be designed to recognize many different species by hybridizing to conserved ("constant") regions and amplifying the variable segments between them that function to identify the species of origin. A problem with current technology is that read length sequencing generally only allows for the analysis of one variable region at a time, and therefore may be limited in its ability to distinguish closely related species. Having a method that can sequence longer stretches of rRNA genes to include multiple variable regions would benefit the community. In this example, the method of the present invention is applied to a metagenomic sample, where rRNA is converted to cDNA using a gene-specific primer that hybridizes to one of the constant regions, thereby generating a cDNA that encompasses some, preferably all, of the variable regions of the rRNA and includes a copy of the TSO. This cDNA is then amplified and fragmented according to the method of the present invention, and the internal and 5'-end fragments are amplified to create a library as described herein. The library is then sequenced. By using paired end reads and the ability to distinguish between 5'-end reads and internal reads as described in the method of the present invention, it is possible to distinguish multiple variable regions belonging to the same original rRNA molecule, thus allowing for improved identification of species present in the metagenomic sample from which the RNA was derived.

[0227] The above embodiments should be understood as some illustrative examples of the present invention. It is understood by those skilled in the art that various modifications, combinations and changes can be made to the embodiments without departing from the scope of the present invention. In particular, different part solutions in different embodiments can be combined in other configurations, if technically possible. However, the scope of the present invention is defined by the appended claims.

[0228] CROSS-REFERENCE TO RELATED APPLICATIONS Pursuant to 35 U.S.C. § 119(e), this application claims priority to the filing date of Swedish Provisional Patent Application Serial No. 1851672-4, filed December 28, 2018, the disclosure of which is incorporated herein by reference.

Claims

1. 1. A method for preparing complementary deoxyribonucleic acid (cDNA), comprising: hybridizing a cDNA synthesis primer to a ribonucleic acid (RNA) molecule and synthesizing a cDNA strand complementary to at least a portion of said RNA molecule to form an RNA-cDNA intermediate; and performing a template switching reaction by contacting the RNA-cDNA intermediate with a template switching oligonucleotide (TSO) under conditions suitable for extending the cDNA strand using the TSO as a template to form an extended cDNA strand complementary to the RNA molecule and at least a portion of the TSO, the TSO comprising an amplification primer site, an identification tag, a unique molecular identifier (UMI), and a plurality of predefined nucleotides, the identification tag distinguishing sequencing reads of 5' UMI-containing fragments from sequencing reads of internal fragments; A method comprising:

2. hybridizing the cDNA synthesis primer comprises hybridizing the cDNA synthesis primer to the RNA molecule and synthesizing the cDNA strand by reverse transcription to form the RNA-cDNA intermediate; 2. The method of claim 1, wherein performing the template switching reaction comprises performing the template switching reaction by contacting the RNA-cDNA intermediate with the TSO under conditions suitable for extension of the cDNA strand by reverse transcription to form the extended cDNA strand.

3. 3. The method of claim 2, wherein the reverse transcription is carried out in the presence of ribonucleotides, at a concentration selected within the interval of 0.05 mM to 10 mM.

4. The reverse transcription is carried out in the presence of a mixture of dATP, dGTP, dTTP and dCTP; the mixture comprises equal concentrations of dATP, dGTP, and dTTP, and a concentration of dCTP that is X mM greater than the same concentrations of dATP, dGTP, and dTTP; 4. The method of claim 2 or 3, wherein XmM is selected within the interval from 0.05 mM to 10 mM.

5. 5. The method according to claim 2, wherein the reverse transcription is carried out in the presence of a magnesium salt at a concentration selected within the interval of 0.1 mM to 20 mM.

6. 6. The method of any of claims 2 to 5, wherein the reverse transcription is carried out in the presence of a chloride salt selected from the group consisting of sodium chloride (NaCl), cesium chloride (CsCl), and mixtures thereof, and is carried out with at least a reduced amount of potassium chloride (KCl).

7. 7. The method of claim 2, wherein the reverse transcription is carried out in the presence of polyethylene glycol (PEG) having an average molecular weight selected within the interval of 300 Da to 100,000 Da.

8. The method of any one of claims 1 to 7, wherein the amplification primer site comprises a portion of a transposase 5 (Tn5) motif sequence.

9. The method of any one of claims 1 to 8, wherein the identification tag comprises a nucleotide sequence that is not present in the transcriptome of the cell from which the RNA molecule is derived.

10. 10. The method of claim 1, wherein the plurality of nucleotides is three ribonucleotides.

11. The method of any one of claims 1 to 10, wherein the cDNA synthesis primer comprises an oligo dT sequence.

12. 12. The method of claim 11, wherein the primer site comprises a nucleotide sequence that is not present in the transcriptome of the cell from which the RNA molecule is derived.

13. hybridizing the cDNA synthesis primer includes, for each RNA molecule of the plurality of RNA molecules, hybridizing the cDNA synthesis primer to the RNA molecule and synthesizing a respective cDNA strand complementary to at least a portion of the RNA molecule to form a respective RNA-cDNA intermediate; 13. The method of any of claims 1 to 12, wherein performing the template switching reaction comprises performing the template switching reaction by contacting the respective RNA-cDNA intermediates with the respective TSOs under conditions suitable for extension of the respective cDNA strands using the respective TSOs as templates to form respective extended cDNA strands complementary to the RNA molecule and at least a portion of the respective TSOs, wherein each TSO comprises the amplification primer site, the identifier tag, a UMI and the plurality of predefined nucleotides, and each TSO comprises a UMI that is unique to the TSO and different from the UMIs of other TSOs.

14. further comprising amplifying the extended cDNA strand using a forward primer and a reverse primer; 14. The method of claim 1, wherein the forward primer comprises the amplification primer site and the identification tag.

15. The method of claim 14, wherein amplification of the extended cDNA strand is performed simultaneously with the template switching reaction.

16. 16. The method of any of claims 1 to 15, further comprising fragmenting and tagging the extended cDNA strand, or an amplified version thereof, in a tagging process using a transposase and at least one tagging adapter to form tagged cDNA fragments.

17. 17. The method of Claim 16, further comprising amplifying the tagged cDNA fragment in the presence of a forward amplification primer and a reverse amplification primer.

18. 18. The method of claim 17, further comprising sequencing the amplified tagged cDNA fragments by the addition of at least one sequencing primer.

19. Preparing tagged cDNA fragments from the RNA molecules according to any one of claims 16 to 18; and adjusting the ratio between the number of tagged cDNA fragments corresponding to the 5'-end portion of the extended cDNA strand and the total number of tagged cDNA fragments; A method for preparing a cDNA library, comprising:

20. Adjusting the ratio includes: Controlling the amount of transposase present in the tagging process according to any one of claims 16 to 18; Controlling the amount of the extended cDNA strand or an amplified version thereof present in the tagging process according to any one of claims 16 to 18; and / or Controlling the reaction time of the tagging process according to any one of claims 16 to 18.

20. The method of claim 19, comprising:

21. A kit for preparing complementary deoxyribonucleic acid (cDNA), comprising: a cDNA synthesis primer configured to hybridize to a ribonucleic acid (RNA) molecule to permit synthesis of a cDNA strand complementary to at least a portion of said RNA molecule to form an RNA-cDNA intermediate; and a template switching oligonucleotide (TSO) comprising an amplification primer site, an identification tag, a unique molecular identifier (UMI), and a plurality of predefined nucleotides, said identification tag distinguishing sequencing reads of a 5' UMI-containing fragment from sequencing reads of an internal fragment; Including, The TSO is configured to serve as a template in a template switching reaction that includes extension of the cDNA strand to form an extended cDNA strand complementary to the RNA molecule and at least a portion of the TSO.

22. 1. A method for preparing a nucleic acid fragment, comprising: hybridizing a cDNA synthesis primer to a ribonucleic acid (RNA) molecule and synthesizing a cDNA strand complementary to at least a portion of said RNA molecule to form an RNA-cDNA intermediate; performing a template switching reaction by contacting the RNA-cDNA intermediate with a template switching oligonucleotide (TSO) under conditions suitable for extension of the cDNA strand using the TSO as a template to form an extended cDNA strand complementary to the RNA molecule and at least a portion of the TSO, the TSO comprising an amplification primer site, an identifier tag, a unique molecular identifier (UMI), and a plurality of predefined nucleotides, the identifier tag distinguishing sequencing reads of 5′ UMI-containing fragments from sequencing reads of internal fragments; generating a double-stranded cDNA from the extended cDNA strand; and fragmenting the double stranded cDNA to generate nucleic acid fragments comprising a first population of 5' UMI containing fragments and a second population of internal fragments. The method includes:

23. 23. The method of claim 22, wherein the cDNA synthesis primer comprises a reverse amplification primer site.

24. 24. The method of claim 22 or 23, wherein the cDNA synthesis primer comprises an oligo-dT RNA binding site or a gene-specific RNA binding site.

25. 25. The method of any of claims 22 to 24, wherein generating double-stranded cDNA comprises amplifying.

26. 26. The method of claim 25, wherein said amplifying comprises employing a forward primer that hybridizes to said amplification primer site, and a reverse primer that hybridizes to said cDNA synthesis primer comprises a reverse amplification primer site.

27. 27. The method of any of claims 22 to 26, wherein fragmenting comprises tagging to generate tagged fragments.

28. 28. The method of claim 27, wherein the amplification primer site comprises a portion of a transposase motif sequence of a transposase used in the tagging.

29. 29. The method of claim 28, wherein the transposase motif is Tn5.

30. 27. The method of any of claims 22 to 26, wherein the fragmenting comprises shearing, sonication, or enzymatic fragmentation.

31. 31. The method of claim 30, further comprising tagging the first population of 5' UMI-containing fragments and the second population of internal fragments with tagging adaptors.

32. 32. The method of Claim 31, wherein the tagging adaptors comprise a first tagging adaptor comprising a read 1 sequencing primer site and a second tagging adaptor comprising a read 2 sequencing primer site.

33. hybridizing the cDNA synthesis primer includes, for each RNA molecule of the plurality of RNA molecules, hybridizing the cDNA synthesis primer to the RNA molecule and synthesizing a respective cDNA strand complementary to at least a portion of the RNA molecule to form a respective RNA-cDNA intermediate; 33. The method of any of claims 22 to 32, wherein performing the template switching reaction comprises performing the template switching reaction by contacting the respective RNA-cDNA intermediates with the respective TSOs under conditions suitable for extension of the respective cDNA strands using a respective TSO as a template to form a respective extended cDNA strand complementary to the RNA molecule and at least a portion of the respective TSO, wherein each TSO comprises the amplification primer site, the identifier tag, a UMI and the plurality of predefined nucleotides, and each TSO comprises a UMI that is unique to the TSO and different from the UMIs of other TSOs.

34. 34. The method of claim 33, wherein the plurality of RNA molecules is derived from a single cell.

35. 34. The method of claim 33, wherein the plurality of RNA molecules is derived from a plurality of cells.

36. 36. The method of any of claims 22-35, further comprising sequencing the first population of 5' UMI-containing fragments and the second population of internal fragments.

37. 37. The method of claim 36, further comprising distinguishing sequencing reads of a first population of 5' UMI-containing fragments from sequencing reads of the internal fragments by the presence of the identifying tag sequence.

38. 38. The method of claim 37, further comprising constructing a full-length sequence of the RNA from sequencing reads of both the 5' UMI-containing fragment and the internal fragment.

39. 39. The method of claim 38, wherein said constructing comprises taking sequencing reads of an internal fragment generated from the same RNA from which said 5' UMI-containing fragment was generated.

40. 40. The method of claim 38 or 39, further comprising assigning an isoform to the RNA.

41. 41. The method of any of claims 38-40, further comprising identifying at least a first SNP in the RNA.

42. 42. The method of claim 41, further comprising identifying at least a second SNP in the RNA.

43. 43. The method of claim 42, further comprising establishing a phase relationship of the first and second SNPs.

44. 40. The method of claim 38 or 39, further comprising identifying the RNA as a product of a gene fusion.

45. hybridizing the cDNA synthesis primer comprises hybridizing the cDNA synthesis primer to the RNA molecule and synthesizing the cDNA strand by reverse transcription to form the RNA-cDNA intermediate; 45. The method of any of claims 22 to 44, wherein performing the template switching reaction comprises performing the template switching reaction by contacting the RNA-cDNA intermediate with the TSO under conditions suitable for extension of the cDNA strand by reverse transcription to form the extended cDNA strand.

46. 46. ​​The method of claim 45, wherein the reverse transcription is carried out in the presence of ribonucleotides, at a concentration selected within the interval of 0.05 mM to 10 mM.

47. The reverse transcription is carried out in the presence of a mixture of dATP, dGTP, dTTP, and dCTP; the mixture comprises equal concentrations of dATP, dGTP, and dTTP, and a concentration of dCTP that is X mM greater than the same concentrations of dATP, dGTP, and dTTP; 47. The method of claim 45 or 46, wherein XmM is selected within the interval from 0.05 mM to 10 mM.

48. 48. The method of any of claims 45 to 47, wherein the reverse transcription is carried out in the presence of a magnesium salt at a concentration selected within the interval of 0.1 mM to 20 mM.

49. 49. The method of any of claims 45 to 48, wherein the reverse transcription is carried out in the presence of a chloride salt selected from the group consisting of sodium chloride (NaCl), cesium chloride (CsCl), and mixtures thereof, with at least a reduced amount of potassium chloride (KCl).

50. 50. The method of any of claims 45 to 49, wherein the reverse transcription is carried out in the presence of polyethylene glycol (PEG) having an average molecular weight selected within the interval of 300 Da to 100,000 Da.

51. A kit for preparing a nucleic acid fragment, comprising: a cDNA synthesis primer configured to hybridize to a ribonucleic acid (RNA) molecule to permit synthesis of a cDNA strand complementary to at least a portion of the RNA molecule to form an RNA-cDNA intermediate, the cDNA synthesis primer including a reverse amplification primer site; and a template switching oligonucleotide (TSO) comprising an amplification primer site, an identifier tag, a unique molecular identifier (UMI), and a plurality of predefined nucleotides, said identifier tag distinguishing a sequencing read of a 5' UMI-containing fragment from a sequencing read of an internal fragment; Including, The TSO is configured to serve as a template in a template switching reaction that includes extension of the cDNA strand to form an extended cDNA strand complementary to the RNA molecule and at least a portion of the TSO.

52. 52. The kit of claim 51, wherein the cDNA synthesis primer comprises an oligo dT RNA binding site.

53. 52. The kit of claim 51, wherein the cDNA synthesis primer comprises a gene specific RNA binding site.

54. 54. The kit of any of claims 51 to 53, wherein the amplification primer site comprises a portion of a transposase motif sequence.

55. 55. The kit of claim 54, wherein the transposase motif is Tn5.

56. The method of claim 3 , wherein the ribonucleotide is a guanine ribonucleotide.

57. 10. The method of claim 9, wherein the nucleotide sequence comprises ATTGCGCAATG (SEQ ID NO:11).

58. The method of claim 10, wherein the three ribonucleotides are three guanine ribonucleotides.

59. 13. The method of claim 12, wherein the nucleotide sequence comprises ACGAGCATCAGCAGCATACGA (SEQ ID NO:25).

60. The method of claim 14, wherein the forward primer comprises, from the 5' to 3' end, a transposase 5 (Tn5) motif sequence and the identification tag.

61. The forward primer comprises TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGATTGCGCAATG (SEQ ID NO: 24); 61. The method of claim 60, wherein the reverse primer comprises ACGAGCATCAGCAGCATACGA (SEQ ID NO: 25).

62. 47. The method of claim 46, wherein the ribonucleotide is a guanine ribonucleotide.

Citation Information

Patent Citations

  • Multiplex analysis of single-cell gene expression using template switching and tagmentation

    JP2017514487A

  • Single-cell nucleic acid sequence analysis

    JP2018526026A

  • Systems and methods for pooling samples from multi-well devices

    WO2017087873A1

  • Methods of preparing nucleic acid libraries and compositions and kits for practicing the same

    WO2018152129A1